

Paul G Richardson

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5949616/paul-g-richardson-publications-by-year.pdf>

Version: 2023-06-06

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

856
papers

71,548
citations

136
h-index

253
g-index

889
ext. papers

81,184
ext. citations

5.7
avg, IF

7.36
L-index

#	Paper	IF	Citations
856	Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study.. <i>Lancet Haematology, the</i> , 2022 ,	14	7
855	Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study.. <i>Lancet Oncology, The</i> , 2022 ,	20.9	10
854	Sinusoidal Obstruction Syndrome/Hepatic Veno-Occlusive Disease 2022 , 143-163		
853	Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics. <i>European Journal of Haematology</i> , 2022 , 108, 73-83	3.6	1
852	An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment.. <i>Therapeutic Advances in Hematology</i> , 2022 , 13, 20406207221088458	5.5	
851	Extramedullary disease in multiple myeloma: a systematic literature review.. <i>Blood Cancer Journal</i> , 2022 , 12, 45	6.7	3
850	Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN.. <i>Blood Cancer Journal</i> , 2022 , 12, 63	6.7	0
849	COVID-19 Vaccine Responsiveness in Patients with Multiple Myeloma and Waldenström Macroglobulinemia. <i>Blood</i> , 2021 , 138, 3801-3801	2.1	0
848	Stem Cell Collection with Daratumumab (DARA)-Based Regimens in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) in the Griffin and Master Studies. <i>Blood</i> , 2021 , 138, 2852-2852	2.1	0
847	CC-92480, a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD) Agent, in Combination with Dexamethasone (DEX) and Bortezomib (BORT) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Phase 1/2 Study CC-92480-MM-002. <i>Blood</i> , 2021 , 138, 2731-2731	2.1	6
846	Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 24 Months of Maintenance. <i>Blood</i> , 2021 , 138, 79-79	2.1	4
845	Late vs Early Response and Depth of Response Are Associated with Improved Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) or Placebo-Lenalidomide-Dexamethasone (pbo-Rd) in the Phase 3 TOURMALINE-MM2 Trial. <i>Blood</i> , 2021 , 138, 2733-2733	2.1	
844	OCEAN (OP-103): Melflufen/Dexamethasone (Dex) Compared with Pomalidomide (Pom)/Dex in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) - Safety and Tolerability Analyses. <i>Blood</i> , 2021 , 138, 2732-2732	2.1	
843	Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Dose-Expansion Phase of the CC-220-MM-001 Trial. <i>Blood</i> , 2021 , 138, 162-162	2.1	3
842	OCEAN (OP-103): Melflufen Plus Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed/Refractory Multiple Myeloma (RRMM) - Impact of Prior Treatments Analysis. <i>Blood</i> , 2021 , 138, 4780-4780	2.1	
841	OCEAN (OP-103): Melflufen/Dexamethasone (Dex) Compared with Pomalidomide (Pom)/Dex in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) - Subgroup Analysis By Prior Alkylator Exposed/Refractory Status. <i>Blood</i> , 2021 , 138, 4779-4779	2.1	
840	Characteristics of a Comprehensive, Continuously Updated Longitudinal Database for Multiple Myeloma. <i>Blood</i> , 2021 , 138, 4969-4969	2.1	

839	Pre-Clinical and Clinical Immunomodulatory Effects of Pomalidomide or CC-92480 in Combination with Bortezomib in Multiple Myeloma. <i>Blood</i> , 2021 , 138, 1613-1613	2.1	0
838	Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston Study. <i>Blood</i> , 2021 , 138, 3793-3793	2.1	0
837	Antibody interference and response kinetics of isatuximab plus pomalidomide and dexamethasone in multiple myeloma. <i>Blood Cancer Journal</i> , 2021 , 11, 169	6.7	1
836	Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myeloma. <i>Nature Cell Biology</i> , 2021 , 23, 1199-1211	22.7	1
835	Reply to G. R. Mohyuddin et al and A. Garfall et al. <i>Journal of Clinical Oncology</i> , 2021 , JCO2102081	2.1	
834	Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis. <i>Leukemia</i> , 2021 , 35, 562-572	10.3	31
833	Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. <i>British Journal of Haematology</i> , 2021 , 194, 496-507	4.4	12
832	Successful treatment of solitary bone plasmacytoma and bone remineralisation with novel biological agents leading to new bone formation - a case series. <i>British Journal of Haematology</i> , 2021 , 193, e36-e38	4.4	
831	Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2021 , 137, 3616-3628	2.1	16
830	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology</i> , 2021 , 22, e105-e118	20.9	32
829	The initial management of multiple myeloma in the era of novel agents: 2021 and beyond. <i>British Journal of Haematology</i> , 2021 , 193, 213-215	4.4	
828	Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma. <i>Blood Cancer Journal</i> , 2021 , 11, 55	6.7	2
827	Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2021 , 14, 59	21.8	6
826	Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation. <i>Blood Cancer Discovery</i> , 2021 , 2, 468-483	5.7	15
825	Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis. <i>Leukemia Research</i> , 2021 , 104, 106576	2.1	10
824	ANCHOR (OP-104): Melflufen plus dexamethasone (dex) and bortezomib (BTZ) in relapsed/refractory multiple myeloma (RRMM) Optimal dose, updated efficacy and safety results.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 8037-8037	2.1	2
823	Multiple myeloma triplet therapies: baseline characteristics and control groups - Authors' reply. <i>Lancet</i> , 2021 , 397, 1621-1623	36.2	
822	Melflufen plus dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) exposed/refractory to prior alkylators: A pooled analysis of the O-12-M1 and HORIZON studies.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 8048-8048	2.1	

821	Perceptions of prognosis in caregivers of multiple myeloma (MM) patients.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 12082-12082	2.1	
820	Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma. <i>Leukemia</i> , 2021 , 35, 3526-3533	10.3	5
819	Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. <i>American Journal of Hematology</i> , 2021 , 96, 708-718	6.9	9
818	Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics. <i>British Journal of Haematology</i> , 2021 , 194, 120-131	4.4	9
817	Distinctive Biomarker Features in The Endotheliopathy of COVID-19 and Septic Syndromes. <i>Shock</i> , 2021 ,	3.2	11
816	Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design. <i>Future Oncology</i> , 2021 , 17, 1987-2003	3.4	8
815	Endothelial dysfunction and its critical role in COVID-19-associated coagulopathy: Defibrotide as an endothelium-protective, targeted therapy. <i>EJHaem</i> , 2021 , 2, 680	0.9	0
814	Is the Endothelium the Missing Link in the Pathophysiology and Treatment of COVID-19 Complications?. <i>Cardiovascular Drugs and Therapy</i> , 2021 , 1	3.8	15
813	Panobinostat From Bench to Bedside: Rethinking the Treatment Paradigm for Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021 , 21, 752-765	0.7	1
812	Defibrotide: potential for treating endothelial dysfunction related to viral and post-infectious syndromes. <i>Expert Opinion on Therapeutic Targets</i> , 2021 , 25, 423-433	6.2	2
811	Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma. <i>Leukemia</i> , 2021 ,	10.3	6
810	Selinexor for the treatment of patients with previously treated multiple myeloma. <i>Expert Review of Hematology</i> , 2021 , 14, 697-706	2.7	3
809	Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis. <i>Haematologica</i> , 2021 , 106, 1182-1187	6.4	16
808	Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH. <i>American Journal of Hematology</i> , 2021 , 96, E5-E8	6.9	9
807	Analysis of Time to Complete Response after Defibrotide Initiation in Patients with Hepatic Venous Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 88.e1-88.e6		2
806	Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study. <i>Lancet Oncology</i> , 2021 , 22, 142-154	20.9	22
805	Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021 , 39, 757-767	2.1	43
804	Overall survival with oral selinexor plus low-dose dexamethasone versus real-world therapy in triple-class-refractory multiple myeloma. <i>EJHaem</i> , 2021 , 2, 48-55	0.9	2

803	Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse. <i>Leukemia</i> , 2021 , 35, 1722-1731	10.3	18
802	Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long-term survival follow-up from the Phase II study O-12-M1. <i>British Journal of Haematology</i> , 2021 , 193, 1105-1109	4.4	6
801	Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial. <i>Lancet Haematology</i> , 2021 , 8, e45-e54	14	38
800	Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degradors of Oncoproteins. <i>Cell Reports</i> , 2021 , 34, 108532	10.3	15
799	Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma. <i>Blood Cancer Journal</i> , 2021 , 11, 20	6.7	6
798	A clinical perspective on plasma cell leukemia; current status and future directions. <i>Blood Cancer Journal</i> , 2021 , 11, 23	6.7	8
797	COVID-19-induced endotheliitis: emerging evidence and possible therapeutic strategies. <i>British Journal of Haematology</i> , 2021 , 193, 43-51	4.4	20
796	Molecular dynamics of targeting CD38 in multiple myeloma. <i>British Journal of Haematology</i> , 2021 , 193, 581-591	4.4	6
795	Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk. <i>American Journal of Hematology</i> , 2021 , 96, 1120-1130	6.9	5
794	Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2430-2442	2.1	18
793	Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in -Mutated Multiple Myeloma. <i>Clinical Cancer Research</i> , 2021 , 27, 6432-6444	12.3	3
792	Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study. <i>Future Oncology</i> , 2021 , 17, 4797-4812	3.4	1
791	A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202). <i>American Journal of Hematology</i> , 2021 , 96, 1595-1603	6.9	6
790	Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis. <i>American Journal of Hematology</i> , 2021 , 96, E423-E427	6.9	3
789	Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study. <i>BMC Cancer</i> , 2021 , 21, 993	4.6	1
788	Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options. <i>Blood Reviews</i> , 2021 , 49, 100808	10.7	9
787	The importance of endothelial protection: the emerging role of defibrotide in reversing endothelial injury and its sequelae. <i>Bone Marrow Transplantation</i> , 2021 , 56, 2889-2896	4.2	1
786	Efficacy and Tolerability of Once-Weekly Selinexor, Bortezomib, and Dexamethasone in Comparison with Standard Twice-Weekly Bortezomib and Dexamethasone in Previously Treated Multiple Myeloma with Renal Impairment: Subgroup Analysis from the BOSTON Study. <i>American Journal of Hematology</i> , 2021 , 96, 1120-1130	6.9	2

785	Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. <i>Lancet, The</i> , 2020 , 396, 1563-1573	36.2	92
784	Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. <i>Blood</i> , 2020 , 136, 936-945	2.1	189
783	Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. <i>Nature Communications</i> , 2020 , 11, 2996	16.9	34
782	The role of high-dose melphalan with autologous stem-cell transplant in multiple myeloma: is it time for a paradigm shift?. <i>British Journal of Haematology</i> , 2020 , 191, 692-703	4.4	10
781	c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma. <i>European Journal of Haematology</i> , 2020 , 105, 35-46	3.6	4
780	Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd. <i>Expert Review of Hematology</i> , 2020 , 13, 421-433	2.7	16
779	Pooled analysis of Day 100 survival for defibrotide-treated patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome and ventilator or dialysis dependence following haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2020 , 190, 583-587	4.4	5
778	Veno-occlusive disease/sinusoidal obstruction syndrome in patients with prior gemtuzumab ozogamicin: literature analysis of survival after defibrotide treatment. <i>Blood Cancer Journal</i> , 2020 , 10, 29	6.7	4
777	Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma. <i>Investigational New Drugs</i> , 2020 , 38, 1448-1453	4.1	30
776	Incidence of Anicteric Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome and Outcomes with Defibrotide following Hematopoietic Cell Transplantation in Adult and Pediatric Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1342-1349	2.1	10
775	Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study. <i>Lancet Haematology, the</i> , 2020 , 7, e395-e407	14	44
774	Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?. <i>Cells</i> , 2020 , 9,	7.6	8
773	Selinexor for the treatment of multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , 2020 , 21, 399-408	3.9	21
772	Clinical benefit of ixazomib plus lenalidomide-dexamethasone in myeloma patients with non-canonical NF- κ B pathway activation. <i>European Journal of Haematology</i> , 2020 , 105, 274-285	3.6	3
771	Randomized, placebo-controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib. <i>EJHaem</i> , 2020 , 1, 94-102	0.9	6
770	Consensus Recommendations for the Clinical Management of Patients With Multiple Myeloma Treated With Selinexor. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, 351-357	0.7	10
769	Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2020 , 61, 1850-1859	1.8	4
768	Defibrotide for the Treatment of Endotheliitis Complicating Sars-Cov-2 Infection: Rationale and Ongoing Studies As Part of the International Defacovid Study Group. <i>Blood</i> , 2020 , 136, 6-8	2.1	1

767	HORIZON (OP-106) Versus MAMMOTH: An Indirect Comparison of Efficacy Outcomes for Patients with Relapsed/Refractory Multiple Myeloma Refractory (RRMM) to Anti-CD38 Monoclonal Antibody Therapy Treated with Melflufen Plus Dexamethasone Versus Conventional Agents. <i>Blood</i> , 2020 , 136, 2-4	2.1	2
766	TRAF2 Mediates Sensitivity to Immunomodulatory Drugs in the Bone Marrow Microenvironment. <i>Blood</i> , 2020 , 136, 31-31	2.1	
765	HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)-Analysis of Adverse Events Related to Hospitalizations. <i>Blood</i> , 2020 , 136, 20-22	2.1	
764	HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) - Health-Related Quality of Life (HRQoL) Analysis. <i>Blood</i> , 2020 , 136, 27-29	2.1	0
763	Variation in the Treatment of Multiple Myeloma in the Real World. <i>Blood</i> , 2020 , 136, 43-44	2.1	
762	Clinical Outcomes of Non-Traditional Lenalidomide, Bortezomib, and Dexamethasone Regimens in Multiple Myeloma. <i>Blood</i> , 2020 , 136, 25-26	2.1	0
761	Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial. <i>Blood</i> , 2020 , 136, 39-39	2.1	26
760	HORIZON (OP-106): Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma with High-Risk Cytogenetics-Subgroup Analysis. <i>Blood</i> , 2020 , 136, 41-43	2.1	3
759	HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) Exposed to Prior Alkylator Therapy-Subgroup Analysis. <i>Blood</i> , 2020 , 136, 22-23	2.1	2
758	HORIZON (OP-106): Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma-Age Subgroup Analysis of Elderly Patients. <i>Blood</i> , 2020 , 136, 44-46	2.1	2
757	Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy. <i>Blood</i> , 2020 , 136, 45-46	2.1	13
756	HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in 55 Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD)-Subgroup Analysis. <i>Blood</i> , 2020 , 136, 15-17	2.1	4
755	First Results of Iberdomide (IBER; CC-220) in Combination with Dexamethasone (DEX) and Daratumumab (DARA) or Bortezomib (BORT) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2020 , 136, 16-17	2.1	16
754	High-Dose Melphalan Significantly Increases Mutational Burden in Multiple Myeloma Cells at Relapse: Results from a Randomized Study in Multiple Myeloma. <i>Blood</i> , 2020 , 136, 4-5	2.1	6
753	Bortezomib Induces Anti-Multiple Myeloma Immune Response Mediated By Cgas/Sting Pathway Activation, Type I Interferon Secretion, and Immunogenic Cell Death: Clinical Application. <i>Blood</i> , 2020 , 136, 7-8	2.1	2
752	A High Throughput Quantitative Seroproteomics Analysis of Multiple Myeloma Patients on Tagraxofusp Therapy Identifies Novel Cytokine-Assisted Mechanism of Action. <i>Blood</i> , 2020 , 136, 34-34	2.1	1
751	Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2380-2389	2.1	46
750	First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 8500-8500	2.1	22

749	DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and renal impairment.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 8519-8519	2.1	7
748	HORIZON (OP-106): An exploratory analysis of time-to-next treatment (TTNT) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) who received melflufen plus dexamethasone (dex).. <i>Journal of Clinical Oncology</i> , 2020 , 38, e20570-e20570	2.1	5
747	Melflufen: A Novel Agent in the Treatment of Relapsed/Refractory Multiple Myeloma. <i>Oncology & Hematology Review</i> , 2020 , 16, 12	0.1	
746	Pomalidomide-bortezomib-dexamethasone in relapsed or refractory multiple myeloma: Japanese subset analysis of OPTIMISMM. <i>Cancer Science</i> , 2020 , 111, 2116-2122	6.7	3
745	Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5	14
744	Pomalidomide, bortezomib, and dexamethasone (PVd) in lenalidomide (LEN)-pretreated relapsed refractory multiple myeloma: Subanalysis of patients with renal impairment in OPTIMISMM.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e20562-e20562	2.1	1
743	Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. <i>Lancet Haematology</i> , 2020 , 7, e447-e455	14	32
742	A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020 , 26, 344-353	12.3	39
741	Incidence, Predictors, and Outcomes of Venous Occlusive Disease/Sinusoidal Obstruction Syndrome after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 529-539	2.1	7
740	Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome: an international expert position statement. <i>Lancet Haematology</i> , 2020 , 7, e61-e72	14	23
739	Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. <i>Lancet Oncology</i> , 2020 , 21, 207-221	20.9	281
738	Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3107-3118	2.1	19
737	Proteasome inhibition for the treatment of glioblastoma. <i>Expert Opinion on Investigational Drugs</i> , 2020 , 29, 1133-1141	5.7	17
736	Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma. <i>Blood</i> , 2020 , 136, 2513-2523	2.1	25
735	Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study. <i>Blood Cancer Journal</i> , 2020 , 10, 106	6.7	20
734	Isatuximab for the treatment of relapsed/refractory multiple myeloma. <i>Expert Opinion on Biological Therapy</i> , 2020 , 20, 1395-1404	5.2	12
733	Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, 797-803	0.7	3
732	Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. <i>Lancet Oncology</i> , 2020 , 21, 1317-1330	20.9	76

731	Melflufen for relapsed and refractory multiple myeloma. <i>Expert Opinion on Investigational Drugs</i> , 2020 , 29, 1069-1078	5.7	10
730	Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group. <i>Bone Marrow Transplantation</i> , 2020 , 55, 485-495	4.2	28
729	Randomized Clinical Trial Representativeness and Outcomes in Real-World Patients: Comparison of 6 Hallmark Randomized Clinical Trials of Relapsed/Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, 8-17.e16	0.7	31
728	Current antibody-based therapies for the treatment of multiple myeloma. <i>Clinical Advances in Hematology and Oncology</i> , 2020 , 18, 736-748	0.6	
727	Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma. <i>American Journal of Hematology</i> , 2019 , 94, 1244-1253	6.9	24
726	Recent developments with defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome. <i>Expert Opinion on Orphan Drugs</i> , 2019 , 7, 337-347	1	3
725	Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance. <i>Leukemia</i> , 2019 , 33, 1736-1746	10.3	29
724	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISM): a randomised, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2019 , 20, 781-794	20.9	150
723	A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma. <i>Blood</i> , 2019 , 134, 123-133	2.1	65
722	Deciphering the chronology of copy number alterations in Multiple Myeloma. <i>Blood Cancer Journal</i> , 2019 , 9, 39	6.7	25
721	Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8 cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy. <i>Leukemia</i> , 2019 , 33, 2208-2226	10.3	20
720	Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study. <i>British Journal of Haematology</i> , 2019 , 186, e35-e39	4.4	10
719	Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies. <i>European Journal of Haematology</i> , 2019 , 102, 494-503	3.6	8
718	Systematic review of defibrotide studies in the treatment of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS). <i>Bone Marrow Transplantation</i> , 2019 , 54, 1951-1962	4.2	29
717	Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 137-144 ¹	2.1	27
716	Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients. <i>Leukemia and Lymphoma</i> , 2019 , 60, 118-123	1.8	12
715	APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications. <i>Leukemia</i> , 2019 , 33, 426-438	10.3	40
714	Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2019 , 381, 727-738	57.2	266

713	Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. <i>Lancet, The</i> , 2019 , 394, 2096-2107	36.2	253
712	Daratumumab + Lenalidomide, Bortezomib & Dexamethasone Improves Depth of Response in Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, e353-e354	0.7	7
711	Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update. <i>Blood</i> , 2019 , 134, 691-691	2.1	31
710	ANCHOR (OP-104): Updated Efficacy and Safety from a Phase 1/2 Study of Melflufen and Dexamethasone Plus Bortezomib or Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD or a Proteasome Inhibitor (PI). <i>Blood</i> , 2019 , 134, 3124-3124	2.1	9
709	Clinical Activity of Melflufen in Patients with Triple-Class Refractory Multiple Myeloma and Poor-Risk Features in an Updated Analysis of HORIZON (OP-106), a Phase 2 Study in Patients with Relapsed/Refractory Multiple Myeloma Refractory to Pomalidomide and/or Daratumumab. <i>Blood</i> , 2019 , 134, 1833-1833	2.1	3
708	Updated Progression-Free Survival (PFS) and Overall Survival (OS) with Melflufen and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 2 Study O-12-M1. <i>Blood</i> , 2019 , 134, 1839-1839	2.1	1
707	A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , 2019 , 134, 3169-3169	2.1	5
706	Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined Analysis of the STORM and Mammoth Studies. <i>Blood</i> , 2019 , 134, 3125-3125	2.1	7
705	Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacytomas. <i>Blood</i> , 2019 , 134, 3140-3140	2.1	4
704	Dreamm-5: Platform Trial Evaluating Belantamab Mafodotin (a BCMA-directed Immuno-conjugate) in Combination with Novel Agents in Relapsed or Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2019 , 134, 1857-1857	2.1	7
703	A phase III randomized, open label, multicenter study comparing isatuximab, pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 8004-8004	2.1	12
702	Overall survival (OS) with oral selinexor plus low dose dexamethasone (Sd) in patients with triple class refractory-multiple myeloma (TCR-MM).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 8014-8014	2.1	8
701	Analysis of time to next treatment (TTNT) in melflufen and dexamethasone-treated patients (pts) with relapsed/refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 8043-8043	2.1	
700	The Burden of Relapsed/Refractory Multiple Myeloma: An Indirect Comparison of Health-Related Quality of Life Burden across Different Types of Advanced Cancers at Baseline and after Treatment Based on HORIZON (OP-106) Study of Melflufen Plus Dexamethasone. <i>Blood</i> , 2019 , 134, 3487-3487	2.1	2
699	Functional Characterization of E3 Ligases and Their Regulators: Therapeutic Implications for Development of New Proteolysis-Targeting Chimeric Degradors of Oncoproteins. <i>Blood</i> , 2019 , 134, 3183-3183	2.1	18
698	Activity of Melflufen in RR MM Patients with Extramedullary Disease in the Phase 2 HORIZON Study (OP-106): Promising Results in a High-Risk Population. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, e352-e353	0.7	2
697	Efficacy of isatuximab/pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA-MM high-risk cytogenetics subgroup analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, e33	0.7	6
696	ICARIA-MM study: efficacy analysis according to prior lines of treatment. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, e245-e246	0.7	4

695	Performance of the International Myeloma Working Group myeloma frailty score among patients 75 and older. <i>Journal of Geriatric Oncology</i> , 2019 , 10, 486-489	2.3	19
694	Autologous Stem-Cell Transplantation Outcomes for Relapsed Metastatic Germ-Cell Tumors in the Modern Era. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, 58-64.e1	3.2	5
693	A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2019 , 25, 478-486	12.3	19
692	Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma. <i>British Journal of Haematology</i> , 2019 , 184, 475-479	4.4	14
691	Treatment of Relapsed/Refractory Patients with Multiple Myeloma. <i>Hematologic Malignancies</i> , 2018 , 73-96	0	1
690	Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results. <i>British Journal of Haematology</i> , 2018 , 180, 821-830	4.4	23
689	Safety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2018 , 53, 942-945	4.2	19
688	Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design. <i>Future Oncology</i> , 2018 , 14, 1035-1047	3.4	56
687	Defibrotide sodium for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome. <i>Expert Review of Clinical Pharmacology</i> , 2018 , 11, 113-124	3.7	23
686	Current use of monoclonal antibodies in the treatment of multiple myeloma. <i>British Journal of Haematology</i> , 2018 , 181, 447-459	4.4	28
685	Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing. <i>Leukemia</i> , 2018 , 32, 1838-1841	10.3	24
684	Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1. <i>Leukemia</i> , 2018 , 32, 2032-2036	10.3	7
683	Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma. <i>British Journal of Haematology</i> , 2018 , 180, 271-275	4.4	16
682	Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma. <i>Clinical Pharmacokinetics</i> , 2018 , 57, 529-538	6	18
681	Maintenance and continuous therapy for multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2018 , 18, 751-764	3.4	9
680	Trial designs for chemotherapy-induced peripheral neuropathy prevention: ACTION recommendations. <i>Neurology</i> , 2018 , 91, 403-413	5.7	42
679	A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. <i>British Journal of Haematology</i> , 2018 , 182, 222-230	4.4	70
678	Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma. <i>American Journal of Hematology</i> , 2018 , 93, 985	6.9	31

677	Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma. <i>British Journal of Haematology</i> , 2018 , 181, 433-446	4.4	25
676	Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical Trial. <i>JAMA Oncology</i> , 2018 , 4, e183267	12.9	45
675	Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome following nontransplant-associated chemotherapy: Final results from a post hoc analysis of data from an expanded-access program. <i>Pediatric Blood and Cancer</i> , 2018 , 65, e27269	2.9	19
674	Health-Related Quality of Life Among Patients with Relapsed or Refractory Multiple Myeloma Who Received Pomalidomide, Bortezomib, and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone - Results from the Phase 3 Optimism Study. <i>Blood</i> , 2018 , 132, 1960-1960	2.1	1
673	The OP-104 Anchor Study: A Phase 1/2 Study of Safety and Efficacy of Melflufen and Dexamethasone in Combination with Either Bortezomib or Daratumumab in Patients with Rrmm; First Report on Phase 1 Data. <i>Blood</i> , 2018 , 132, 1967-1967	2.1	2
672	Survival Analysis from the CALGB Study of Lenalidomide Maintenance Therapy in Newly Diagnosed Multiple Myeloma Post-Autologous Stem Cell Transplantation Adjusted for Crossover (Alliance 100104). <i>Blood</i> , 2018 , 132, 4737-4737	2.1	4
671	The Role of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Multiple Myeloma: Immunomodulator Maintenance Post Autologous Stem Cell Transplant (ASCT) Predicts Better Outcome. <i>Blood</i> , 2018 , 132, 749-749	2.1	6
670	OP-106 Horizon [Melflufen Therapy for RRMM Patients Refractory to Daratumumab and/or Pomalidomide; Updated Results and First Report on PFS. <i>Blood</i> , 2018 , 132, 600-600	2.1	9
669	Results of the Pivotal STORM Study (Part 2) in Penta-Refractory Multiple Myeloma (MM): Deep and Durable Responses with Oral Selinexor Plus Low Dose Dexamethasone in Patients with Penta-Refractory MM. <i>Blood</i> , 2018 , 132, 598-598	2.1	9
668	Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma. <i>Blood</i> , 2018 , 132, 804-804	2.1	14
667	Pomalidomide (POM), bortezomib, and low-dose dexamethasone (PVd) vs bortezomib and low-dose dexamethasone (Vd) in lenalidomide (LEN)-exposed patients (pts) with relapsed or refractory multiple myeloma (RRMM): Phase 3 OPTIMISM trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 8001-8001	2.1	15
666	Final results of a phase Ib study of isatuximab (ISA) plus pomalidomide (Pom) and dexamethasone (dex) in relapsed/refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 8038-8038	2.1	4
665	Evaluation of Infusion Reactions in Patients Receiving Daratumumab Post-Implementation of an Augmented Pre- and Peri-Medication Regimen. <i>Blood</i> , 2018 , 132, 3234-3234	2.1	
664	A Phase Ib/II Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564) in Combination with Lenalidomide Plus Low-Dose Dexamethasone, or with Bortezomib Plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2018 , 132, 3263-3263	2.1	
663	Addition of Ixazomib to an Rd Backbone Improves Clinical Benefit in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) with Non-Canonical NF-KB Activation [Results from the Tourmaline-MM1 Study. <i>Blood</i> , 2018 , 132, 473-473	2.1	
662	A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RVD) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma: Promising Activity and Manageable Toxicity, Including in High Risk Disease. <i>Blood</i> , 2018 , 132, 1981-1981	2.1	0
661	CRISPR-Based Functional Genomics Studies Reveal Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degradors of Oncoproteins: Implications for Novel Therapeutics across Diverse Neoplasias. <i>Blood</i> , 2018 , 132, 1367-1367	2.1	
660	A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results. <i>British Journal of Haematology</i> , 2018 , 180, 41-51	4.4	41

659	CD38 antibodies in multiple myeloma: back to the future. <i>Blood</i> , 2018 , 131, 13-29	2.1	209
658	The use of defibrotide in blood and marrow transplantation. <i>Blood Advances</i> , 2018 , 2, 1495-1509	7.5	31
657	Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. <i>Blood Cancer Journal</i> , 2018 , 8, 109	6.7	97
656	The power of proteasome inhibition in multiple myeloma. <i>Expert Review of Proteomics</i> , 2018 , 15, 1033-1052	4.2	25
655	Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. <i>Lancet Oncology</i> , 2018 , 19, 1641-1653	20.9	141
654	Ixazomib for the treatment of multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , 2018 , 19, 1949-1968	3.9	32
653	Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2018 , 379, 1811-1822	57.2	268
652	Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. <i>Blood</i> , 2018 , 132, 2456-2464	2.1	191
651	Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial. <i>Cancer</i> , 2018 , 124, 4032-4043	6.2	82
650	Phase 2b Results of the STORM Study: Oral Selinexor plus Low Dose Dexamethasone (Sd) in Patients with Penta-Refractory Myeloma (penta-MM). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018 , 18, S249-S250	0.7	6
649	Patient-reported outcomes of multiple myeloma patients treated with panobinostat after ≥ lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled PANORAMA-1 trial. <i>British Journal of Haematology</i> , 2018 , 181, 628-636	4.4	12
648	Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study. <i>British Journal of Haematology</i> , 2018 , 182, 495-503	4.4	23
647	Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome. <i>British Journal of Haematology</i> , 2018 , 181, 816-827	4.4	59
646	How I treat the young patient with multiple myeloma. <i>Blood</i> , 2018 , 132, 1114-1124	2.1	28
645	Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma. <i>British Journal of Haematology</i> , 2018 , 182, 231-244	4.4	23
644	Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2017 , 23, 3307-3315	12.3	148
643	Deacetylase inhibitors: an advance in myeloma therapy?. <i>Expert Review of Hematology</i> , 2017 , 10, 229-237	2.7	24
642	p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma. <i>Blood</i> , 2017 , 129, 1308-1319	2.1	26

641	Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. <i>British Journal of Haematology</i> , 2017 , 178, 571-582	4.4	39
640	A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma. <i>British Journal of Haematology</i> , 2017 , 178, 547-560	4.4	38
639	Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation. <i>British Journal of Haematology</i> , 2017 , 178, 112-118	4.4	46
638	Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis. <i>European Journal of Haematology</i> , 2017 , 99, 199-206	3.6	15
637	Impact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myeloma. <i>British Journal of Haematology</i> , 2017 , 178, 756-763	4.4	14
636	Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. <i>New England Journal of Medicine</i> , 2017 , 376, 1311-1320	57.2	608
635	IgM myeloma: A multicenter retrospective study of 134 patients. <i>American Journal of Hematology</i> , 2017 , 92, 746-751	6.9	21
634	Marizomib for central nervous system-multiple myeloma. <i>British Journal of Haematology</i> , 2017 , 177, 221-225	4.4	38
633	Role of F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. <i>Lancet Oncology</i> , 2017 , 18, e206-e217	20.9	275
632	Defibrotide for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 997-1004	2.1	39
631	Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. <i>Blood</i> , 2017 , 130, 2610-2618	2.1	69
630	Realgar nanoparticles versus ATO arsenic compounds induce <i>in vitro</i> and <i>in vivo</i> activity against multiple myeloma. <i>British Journal of Haematology</i> , 2017 , 179, 756-771	4.4	13
629	Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study. <i>Journal of Hematology and Oncology</i> , 2017 , 10, 137	21.8	37
628	Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3279-3289	2.1	361
627	Prospective Evaluation of Magnetic Resonance Imaging and [F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2911-2918	2.1	172
626	Melflufen - a peptidase-potentiated alkylating agent in clinical trials. <i>Oncotarget</i> , 2017 , 8, 66641-66655	3.2	43
625	Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses. <i>Targeted Oncology</i> , 2017 , 12, 643-654	4.8	16
624	Defibrotide for children and adults with hepatic veno-occlusive disease post hematopoietic cell transplantation. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017 , 11, 885-898	4.1	16

623	Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. <i>Lancet Haematology</i> , 2017 , 4, e431-e442	14	93
622	Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized Trial. <i>Annals of Internal Medicine</i> , 2017 , 167, 384-393	7.8	23
621	IgA multiple myeloma in a patient with an IgG pemphigus foliaceus-like exanthem. <i>International Journal of Dermatology</i> , 2017 , 56, 1058-1060	1.7	0
620	Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agent. <i>Expert Review of Hematology</i> , 2017 , 10, 933-939	2.7	8
619	Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. <i>British Journal of Haematology</i> , 2017 , 178, 896-905	4.4	101
618	Consensus Report by Pediatric Acute Lung Injury and Sepsis Investigators and Pediatric Blood and Marrow Transplantation Consortium Joint Working Committees: Supportive Care Guidelines for Management of Venous Occlusive Disease in Children and Adolescents, Part 1: Focus on	2.1	21
617	Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone . placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1. <i>Haematologica</i> , 2017 , 102, 1767-1775	6.4	36
616	The proteasome and proteasome inhibitors in multiple myeloma. <i>Cancer and Metastasis Reviews</i> , 2017 , 36, 561-584	9.2	150
615	Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against. <i>Expert Opinion on Pharmacotherapy</i> , 2017 , 18, 1975-1985	3.9	8
614	Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017 , 17, 555-562	0.7	18
613	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. <i>Blood</i> , 2017 , 130, 1198-1204	2.1	46
612	Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial. <i>British Journal of Haematology</i> , 2017 , 179, 66-74	4.4	12
611	Deacetylase inhibitors as a novel modality in the treatment of multiple myeloma. <i>Pharmacological Research</i> , 2017 , 117, 185-191	9.9	19
610	Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies: A Review. <i>JAMA Oncology</i> , 2017 , 3, 980-988	12.9	53
609	Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome with multiorgan failure. <i>International Journal of Hematologic Oncology</i> , 2017 , 6, 75-93	0.9	16
608	New developments in the management of relapsed/refractory multiple myeloma - the role of ixazomib. <i>Journal of Blood Medicine</i> , 2017 , 8, 107-121	2.2	17
607	Deep and Durable Responses in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (MM) Treated with Monotherapy GSK2857916, an Antibody Drug Conjugate Against B-Cell Maturation Antigen (BCMA): Preliminary Results from Part 2 of Study BMA117159. <i>Blood</i> , 2017 , 130, 741-741	2.1	30
606	CALGB/ECOG 100104 (Alliance) study: Lenalidomide (LEN) vs placebo (PBO) maintenance (maint) after stem cell transplant (SCT) for patients (pts) with multiple myeloma Overall survival (OS) and progression-free survival (PFS) adjusted for treatment (tx) crossover (XO).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2027-2027	2.1	1

605	Efficacy and Safety of Long-Term Ixazomib Maintenance Therapy in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Not Undergoing Transplant: An Integrated Analysis of Four Phase 1/2 Studies. <i>Blood</i> , 2017 , 130, 902-902	2.1	3
604	Hematopoietic Cell Transplantation in Patients with Medication-Related Osteonecrosis of the Jaws. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 344-348	2.1	4
603	Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma. <i>Expert Opinion on Biological Therapy</i> , 2016 , 16, 1291-301	5.2	10
602	Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial. <i>Lancet Oncology, The</i> , 2016 , 17, 1569-1578	20.9	133
601	APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. <i>Blood</i> , 2016 , 127, 3225-36	2.1	168
600	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. <i>Lancet Oncology, The</i> , 2016 , 17, e328-e346	20.9	1155
599	Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial. <i>Lancet Haematology, the</i> , 2016 , 3, e506-e515	14	98
598	Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, 13162-13167	11.1	89
597	Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials. <i>Leukemia and Lymphoma</i> , 2016 , 57, 2833-2838	1.8	23
596	A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells. <i>British Journal of Haematology</i> , 2016 , 174, 397-409	4.4	33
595	Multiple Myeloma in Pregnancy--A Review of the Literature and a Case Series. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016 , 16, e39-45	0.7	9
594	Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution. <i>Clinical Cancer Research</i> , 2016 , 22, 4206-4214	12.3	18
593	International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1544-57	2.1	204
592	Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. <i>Lancet, The</i> , 2016 , 387, 1551-1560	36.2	581
591	The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival. <i>Nature Communications</i> , 2016 , 7, 10258	16.9	61
590	Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes. <i>Expert Review of Clinical Pharmacology</i> , 2016 , 9, 35-48	3.7	19
589	First in Human Study with GSK2857916, an Antibody Drug Conjugated to Microtubule-Disrupting Agent Directed Against B-Cell Maturation Antigen (BCMA) in Patients with Relapsed/Refractory Multiple Myeloma (MM): Results from Study BMA117159 Part 1 Dose Escalation. <i>Blood</i> , 2016 , 128, 1148-1148	2.1	20
588	Final Results of a Phase 1/2 Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of Evofosfamide, a Hypoxia-Activated Prodrug, and Dexamethasone with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2016 , 128, 2122-2122	2.1	1

587	Preliminary Results from a Phase Ib Study of Isatuximab in Combination with Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , 2016 , 128, 2123-2123	2.1	19
586	Higher c-MYC Expression Is Associated with Ixazomib-Lenalidomide-Dexamethasone (IRd) Progression-Free Survival (PFS) Benefit Versus Placebo-Rd: Biomarker Analysis of the Phase 3 Tourmaline-MM1 Study in Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2016 , 128, 243-243	2.1	3
585	Pmd-107: Marizomib, Pomalidomide and Low Dose-Dexamethasone Combination Study in Relapsed/Refractory Multiple Myeloma (NCT02103335): Full Enrollment Results from a Phase-1 Multicenter, Open Label Study. <i>Blood</i> , 2016 , 128, 3326-3326	2.1	6
584	Timing of Initiation of Defibrotide Post-Diagnosis of Hepatic Venous Occlusive Disease/Sinusoidal Obstruction Syndrome Post-Hematopoietic Stem Cell Transplantation: Exploratory Age-Group Analysis from an Expanded Access Study. <i>Blood</i> , 2016 , 128, 66-66	2.1	3
583	Final Results of a Phase 2 Trial of Extended Treatment (tx) with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (KRd) Plus Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM). <i>Blood</i> , 2016 , 128, 675-675	2.1	34
582	Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma. <i>Blood</i> , 2016 , 128, 976-976	2.1	13
581	Phase 1b study of panobinostat in combination with lenalidomide, bortezomib, and dexamethasone in relapsed refractory multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 8014-8014	2.1	6
580	IgM Myeloma: A Multicenter Retrospective Study of 159 Patients. <i>Blood</i> , 2016 , 128, 3276-3276	2.1	
579	Longer Time to Best Response and Depth of Response Are Associated with Improved Duration of Best Achieved Response and Progression-Free Survival (PFS): Post-Hoc Analysis of Phase 3 Tourmaline-MM1 Trial in Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2016 , 128, 2134-2134	2.1	
578	Identification and Validation of HLA-A24 XBP1us, XBP1sp, CD138, and CS1 Peptides to Generate Antigen Specific-Cytotoxic T Lymphocytes: Preclinical Basis for Vaccine Therapy in HLA-A24 Patients with Multiple Myeloma and Other Cancers. <i>Blood</i> , 2016 , 128, 5689-5689	2.1	
577	A Pilot Study of Eltrombopag Plus G-CSF for Human CD34+ Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplant. <i>Blood</i> , 2016 , 128, 5815-5815	2.1	
576	A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications. <i>Oncotarget</i> , 2016 , 7, 77326-77341	3.2	33
575	TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia. <i>American Journal of Hematology</i> , 2016 , 91, 400-5	6.9	73
574	Clinical utility of C-terminal telopeptide of type 1 collagen in multiple myeloma. <i>British Journal of Haematology</i> , 2016 , 173, 82-8	4.4	10
573	Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma. <i>Blood</i> , 2016 , 128, 1821-1828	2.1	82
572	Dual inhibition of oncogenic targets for B-cell malignancies. <i>Lancet Oncology</i> , 2016 , 17, 547-9	20.9	2
571	Defibrotide for Treatment of Severe Venous Occlusive Disease in Pediatrics and Adults: An Exploratory Analysis Using Data from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1306-1312	2.1	40
570	The Future of Myeloma Therapy: One Size Does Not Fit All. <i>Journal of Oncology Practice</i> , 2016 , 12, 295-63		1

569	Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2016 , 374, 1621-34	57.2	684
568	Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells. <i>Blood</i> , 2016 , 127, 1138-50	2.1	68
567	Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. <i>Blood</i> , 2016 , 127, 681-95	2.1	154
566	Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. <i>Blood</i> , 2016 , 127, 1656-65	2.1	184
565	Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1. <i>Blood</i> , 2016 , 127, 2693-700	2.1	57
564	Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. <i>Blood</i> , 2016 , 128, 37-44	2.1	272
563	Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. <i>Blood</i> , 2016 , 127, 713-21	2.1	99
562	Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2016 , 22, 5688-5695	12.3	17
561	Treatment of Relapsed/Refractory Multiple Myeloma. <i>Cancer Treatment and Research</i> , 2016 , 169, 169-194	3.4	6
560	Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2016 , 375, 1319-1331	57.2	930
559	Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease: Final Results From the International Compassionate-Use Program. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1874-1882	2.1	57
558	Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients. <i>British Journal of Haematology</i> , 2016 , 174, 711-20	4.4	33
557	Promising therapies in multiple myeloma. <i>Blood</i> , 2015 , 126, 300-10	2.1	71
556	Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2863-9	2.1	976
555	Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2015 , 15, 737-48	3.4	43
554	Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2015 , 21, 4607-18	12.3	214
553	Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma. <i>Cancer Discovery</i> , 2015 , 5, 972-87	23.4	67
552	CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon. <i>Clinical Cancer Research</i> , 2015 , 21, 2660-2	12.3	36

551	Proteomic profiling of naïve multiple myeloma patient plasma cells identifies pathways associated with favourable response to bortezomib-based treatment regimens. <i>British Journal of Haematology</i> , 2015 , 170, 66-79	4.4	11
550	The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma. <i>Future Oncology</i> , 2015 , 11, 1153-68	3.4	23
549	Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations. <i>British Journal of Haematology</i> , 2015 , 169, 843-50	4.4	42
548	American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 2039-2051	2.1	114
547	Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. <i>New England Journal of Medicine</i> , 2015 , 373, 1207-19	57.2	761
546	Panobinostat for the Treatment of Multiple Myeloma. <i>Clinical Cancer Research</i> , 2015 , 21, 4767-73	12.3	150
545	Current treatment landscape for relapsed and/or refractory multiple myeloma. <i>Nature Reviews Clinical Oncology</i> , 2015 , 12, 42-54	18.8	146
544	Resolving the daratumumab interference with blood compatibility testing. <i>Transfusion</i> , 2015 , 55, 1545-548		158
543	Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma. <i>Haematologica</i> , 2015 , 100, 100-6	6.4	31
542	Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. <i>Blood</i> , 2015 , 125, 2068-74	2.1	426
541	Guidelines for determination of the number of prior lines of therapy in multiple myeloma. <i>Blood</i> , 2015 , 126, 921-2	2.1	38
540	Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomide. <i>British Journal of Haematology</i> , 2015 , 171, 798-812	4.4	34
539	Combination of a Selective HSP90 α Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells. <i>PLoS ONE</i> , 2015 , 10, e0143847	3.6	16
538	Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2015 , 373, 621-31	57.2	935
537	Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study. <i>Lancet Haematology</i> , 2015 , 2, e516-27	14	129
536	Defibrotide for the treatment of severe hepatic veno-occlusive disease/sinusoidal obstruction syndrome: evidence for clinical benefit. <i>Expert Opinion on Orphan Drugs</i> , 2015 , 3, 1491-1501	1	1
535	Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study. <i>American Journal of Hematology</i> , 2015 , 90, 314-9	6.9	50
534	Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease: An Analysis of Clinical Benefit As Determined By Number Needed to Treat (NNT) to Achieve Complete Response and to Improve Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, S110	2.1	2

533	Management of relapsed multiple myeloma after autologous stem cell transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 793-8	2.1	19
532	Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma: Phase 1b Results (ACY-100 Study). <i>Blood</i> , 2015 , 126, 1827-1827	2.1	10
531	Mutational Profile and Prognostic Relevance of Circulating Tumor Cells in Multiple Myeloma. <i>Blood</i> , 2015 , 126, 23-23	2.1	10
530	Eloquent-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - 3-Year Safety and Efficacy Follow-up. <i>Blood</i> , 2015 , 126, 28-28	2.1	22
529	A Novel Agent SL-401 Triggers Anti-Myeloma Activity By Targeting Plasmacytoid Dendritic Cells: Implications for a Novel Immune-Associated Mechanism. <i>Blood</i> , 2015 , 126, 3000-3000	2.1	1
528	Efficacy of Melflufen, a Peptidase Targeted Therapy, and Dexamethasone in an Ongoing Open-Label Phase 2a Study in Patients with Relapsed and Relapsed-Refractory Multiple Myeloma (RRMM) Including an Initial Report on Progression Free Survival. <i>Blood</i> , 2015 , 126, 3029-3029	2.1	1
527	Analysis of Pomalidomide Plus Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma with Vs without Moderate Renal Impairment. <i>Blood</i> , 2015 , 126, 3031-3031	2.1	3
526	A Phase 1, Multicenter Study of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Patients with Proteasome Inhibitor Exposed and Lenalidomide-Refractory Myeloma (Trial MM-005). <i>Blood</i> , 2015 , 126, 3036-3036	2.1	10
525	ACY-241, a Novel, HDAC6 Selective Inhibitor: Synergy with Immunomodulatory (IMiD [®]) Drugs in Multiple Myeloma (MM) Cells and Early Clinical Results (ACE-MM-200 Study). <i>Blood</i> , 2015 , 126, 3040-3040 ^{2.1}	2.1	15
524	Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and Relapsed-and-Refractory Multiple Myeloma: Phase 1b Results (ACE-MM-101 Study). <i>Blood</i> , 2015 , 126, 3055-3055	2.1	5
523	Alliance A061202. a Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib Versus Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor Based Therapy: Phase I Results. <i>Blood</i> , 2015 , 126, 375-375	2.1	17
522	Autologous Transplantation for Multiple Myeloma in the Era of New Drugs: A Phase III Study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 Trial). <i>Blood</i> , 2015 , 126, 391-391	2.1	80
521	Prospective Evaluation of MRI and PET-CT at Diagnosis and before Maintenance Therapy in Symptomatic Patients with Multiple Myeloma Included in the IFM/DFCI 2009 Trial. <i>Blood</i> , 2015 , 126, 395-395 ^{2.1}	2.1	12
520	A Phase II Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVD-lite) for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2015 , 126, 4217-4217	2.1	7
519	Phase 1, Multicenter, Open-Label, Combination Study (NPI-0052-107; NCT02103335) of Pomalidomide (POM), Marizomib (MRZ, NPI-0052), and Low-Dose Dexamethasone (LD-DEX) in Patients with Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , 2015 , 126, 4220-4220	2.1	7
518	Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, Combines Safely with Pomalidomide and Dexamethasone and Shows Promising Early Results in Relapsed-and-Refractory Myeloma (ACE-MM-102 Study). <i>Blood</i> , 2015 , 126, 4228-4228	2.1	17
517	Updated Results of a Phase 1/2a, Dose Escalation Study of Pvx-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM). <i>Blood</i> , 2015 , 126, 4246-4246	2.1	2
516	Final Results of the Phase I/II Study of Chemosensitization Using the CXCR4 Inhibitor Plerixafor in Combination with Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2015 , 126, 4256-4256	2.1	4

515	Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study (GEN503). <i>Blood</i> , 2015 , 126, 507-507	2.1	25
514	Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with Multi-Organ Dysfunction: Final Results from a Pivotal, Historically Controlled, Phase 3 Trial. <i>Blood</i> , 2015 , 126, 737-737	2.1	1
513	Panobinostat plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma who received prior bortezomib and IMiDs: A predefined subgroup analysis of PANORAMA 1.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 8526-8526	2.1	5
512	Activation of Lysosomal Function and Reactive Oxygen Species Play Crucial Roles in SAR650984-Induced Direct Killing of Human Multiple Myeloma Cells with Mutated p53, Which Is Further Augmented By Pomalidomide. <i>Blood</i> , 2015 , 126, 4253-4253	2.1	
511	Low-Risk Multiple Myeloma By SKY92+ISS Validated in the Multiple Myeloma Genomics Initiative Study. <i>Blood</i> , 2015 , 126, 5322-5322	2.1	
510	Targeting Replicative Stress to Treat Hematological Disorders. <i>Blood</i> , 2015 , 126, 2419-2419	2.1	
509	Monoclonal antibodies in myeloma. <i>Clinical Advances in Hematology and Oncology</i> , 2015 , 13, 599-609	0.6	24
508	A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. <i>Blood</i> , 2014 , 123, 1461-9	2.1	152
507	Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. <i>Cancer Cell</i> , 2014 , 25, 91-101	23.1	657
506	The comprehensive clinical management of multiple myeloma and related-plasma cell disorders. <i>Expert Review of Hematology</i> , 2014 , 7, 1-3	2.7	4
505	Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. <i>Lancet Oncology</i> , 2014 , 15, 333-42	20.9	206
504	Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers. <i>Nature Medicine</i> , 2014 , 20, 599-606	49.3	189
503	Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. <i>Nature Communications</i> , 2014 , 5, 2997	16.9	564
502	International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. <i>Journal of Clinical Oncology</i> , 2014 , 32, 587-600	2.1	255
501	Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma. <i>British Journal of Haematology</i> , 2014 , 167, 127-31	4.4	16
500	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. <i>Lancet Oncology</i> , 2014 , 15, e538-48	20.9	2253
499	Novel targeted agents in the treatment of multiple myeloma. <i>Hematology/Oncology Clinics of North America</i> , 2014 , 28, 903-25	3	14
498	Allogeneic transplantation in multiple myeloma: a potential renaissance in the era of novel therapies?. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1078-9	2.1	1

497	Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. <i>Lancet Oncology, The</i> , 2014 , 15, 1195-206	20.9	604
496	The challenge of cross-trial comparisons using limited data. <i>Haematologica</i> , 2014 , 99, e145-6	6.4	6
495	Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. <i>Blood</i> , 2014 , 123, 632-9	2.1	81
494	Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. <i>Blood</i> , 2014 , 123, 3128-38	2.1	273
493	Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. <i>Blood</i> , 2014 , 123, 1826-32	2.1	271
492	Differential and limited expression of mutant alleles in multiple myeloma. <i>Blood</i> , 2014 , 124, 3110-7	2.1	42
491	Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy. <i>Haematologica</i> , 2014 , 99, 1114-22	6.4	35
490	Pomalidomide for the treatment of relapsed and refractory multiple myeloma. <i>Expert Opinion on Orphan Drugs</i> , 2014 , 2, 1089-1108	1	
489	A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. <i>Blood</i> , 2014 , 123, 706-16	2.1	215
488	Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition. <i>Cancer Research</i> , 2014 , 74, 4458-69	9.6	50
487	Best treatment strategies in high-risk multiple myeloma: navigating a gray area. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2125-32	2.1	20
486	Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. <i>Blood</i> , 2014 , 124, 1038-46	2.1	171
485	Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all?. <i>Hematology American Society of Hematology Education Program</i> , 2014 , 2014, 255-61	2.9	20
484	Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. <i>Lancet Oncology, The</i> , 2014 , 15, 1503-1512	20.9	207
483	Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide. <i>British Journal of Haematology</i> , 2014 , 166, 401-9	4.4	30
482	Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy. <i>Clinical Cancer Research</i> , 2014 , 20, 3955-61	12.3	27
481	Treatment of Multiple Myeloma 2014 , 358-365		
480	Current strategies for treatment of relapsed/refractory multiple myeloma. <i>Expert Review of Hematology</i> , 2014 , 7, 97-111	2.7	58

479	Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all?. <i>Hematology American Society of Hematology Education Program</i> , 2014 , 2014, 255-261	2.9	14
478	Defibrotide for the Treatment of Hepatic Venous Occlusive Disease: An Update from the International Compassionate Use Program in 710 Patients. <i>Blood</i> , 2014 , 124, 1138-1138	2.1	1
477	Identification Rate of Myeloma-Specific Clonotypes in Multiple Diagnostic Sample Types from Patients with Multiple Myeloma Using Next-Generation Sequencing Method. <i>Blood</i> , 2014 , 124, 2036-2036 ¹	2.1	1
476	Characterization of the Incidence and Management of Gastrointestinal Toxicity in the Phase 3 Panorama 1 Study of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , 2014 , 124, 3123-3123	2.1	4
475	Final Results of Phase I/II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Combination with Bortezomib and Rituximab (RVR) in Relapsed or Refractory Waldenstrom Macroglobulinemia. <i>Blood</i> , 2014 , 124, 3081-3081	2.1	3
474	Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase 2 Results. <i>Blood</i> , 2014 , 124, 31-31	2.1	8
473	Oprozomib and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Initial Results from the Dose Escalation Portion of a Phase 1b/2, Multicenter, Open-Label Study. <i>Blood</i> , 2014 , 124, 3453-3453	2.1	15
472	Phase Ib Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564) in Combination with Lenalidomide Plus Low-Dose Dexamethasone, or with Bortezomib plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2014 , 124, 3483-3483	2.1	13
471	Phase 1B Results of Ricolinostat (ACY-1215) Combination Therapy with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma (MM). <i>Blood</i> , 2014 , 124, 4764-4764	2.1	10
470	Ricolinostat (ACY-1215), a Selective HDAC6 Inhibitor, in Combination with Lenalidomide and Dexamethasone: Results of a Phase 1b Trial in Relapsed and Relapsed Refractory Multiple Myeloma. <i>Blood</i> , 2014 , 124, 4772-4772	2.1	6
469	Alternative Splicing Is a Frequent Event and Impacts Clinical Outcome in Myeloma: A Large RNA-Seq Data Analysis of Newly-Diagnosed Myeloma Patients. <i>Blood</i> , 2014 , 124, 638-638	2.1	1
468	Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients (Pts) with Previously Untreated Multiple Myeloma (MM): Phase 2 Study Results. <i>Blood</i> , 2014 , 124, 82-82	2.1	15
467	Effect of combination of proteasome inhibitor marizomib and immunomodulatory agent pomalidomide on synergistic cytotoxicity in multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8588-8588	2.1	4
466	Resistance to Proteasome Inhibitors in Multiple Myeloma. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2014 , 47-80	0.3	3
465	Pulmonary and Hepatic Complications of Hematopoietic Cell Transplantation. <i>Pediatric Oncology</i> , 2014 , 77-102	0.5	1
464	SL-401, a Novel Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Blocks Plasmacytoid Dendritic Cell (pDC)-Triggered Myeloma Cell Growth and Prevents Osteoclastogenesis. <i>Blood</i> , 2014 , 124, 3441-3441	2.1	0
463	Mimicking Myeloma Niche Ex Vivo. <i>Blood</i> , 2014 , 124, 2076-2076	2.1	
462	Evaluation of Immune Profile in Patients with Multiple Myeloma Using Cytof Technology. <i>Blood</i> , 2014 , 124, 3404-3404	2.1	

461	Targeting Immune Suppressive Microenvironment By Immune Checkpoint Blockade in Multiple Myeloma. <i>Blood</i> , 2014 , 124, 27-27	2.1	1
460	Updated Results from a Large, Ongoing, Treatment IND Study Using Defibrotide for Patients with Hepatic Venous Occlusive Disease. <i>Blood</i> , 2014 , 124, 2470-2470	2.1	
459	Inter and Intra-Clonal Heterogeneity in Multiple Myeloma and Waldenstrom Macroglobulinemia. <i>Blood</i> , 2014 , 124, 2070-2070	2.1	
458	Histone deacetylase inhibitors in multiple myeloma: rationale and evidence for their use in combination therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013 , 13, 370-6	0.7	39
457	Conservative management of bisphosphonate-related osteonecrosis of the jaws: staging and treatment outcomes. <i>Oral Oncology</i> , 2013 , 49, 977-983	4.2	40
456	The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias. <i>Cancer Chemotherapy and Pharmacology</i> , 2013 , 71, 1357-68	3.4	53
455	Evolving strategies in the initial treatment of multiple myeloma. <i>Seminars in Oncology</i> , 2013 , 40, 592-601	5.3	5
454	Clinical translation in multiple myeloma: from bench to bedside. <i>Seminars in Oncology</i> , 2013 , 40, 549-553	5.3	7
453	Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma. <i>Leukemia Research</i> , 2013 , 37, 829-37	2.1	44
452	Elotuzumab: a novel anti-CS1 monoclonal antibody for the treatment of multiple myeloma. <i>Expert Opinion on Biological Therapy</i> , 2013 , 13, 1731-40	5.2	28
451	Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. <i>Blood</i> , 2013 , 121, 2975-87	2.1	268
450	Pomalidomide: new immunomodulatory agent with potent antiproliferative effects. <i>Critical Reviews in Oncology/Hematology</i> , 2013 , 88 Suppl 1, S36-44	6.8	24
449	Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study. <i>British Journal of Haematology</i> , 2013 , 160, 351-8	4.4	16
448	New Insights into the Treatment of Multiple Myeloma with Histone Deacetylase Inhibitors. <i>Current Pharmaceutical Design</i> , 2013 , 19, 734-744	3.1	35
447	In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells. <i>Clinical Cancer Research</i> , 2013 , 19, 3019-31	12.3	64
446	Kidney disease and multiple myeloma. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013 , 8, 2007-17	6.7	93
445	Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. <i>Journal of Clinical Oncology</i> , 2013 , 31, 448-55	2.1	211
444	Drug safety evaluation of defibrotide. <i>Expert Opinion on Drug Safety</i> , 2013 , 12, 123-36	4	58

443	Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. <i>Blood</i> , 2013 , 121, 1961-7	2.1	132
442	Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3696-703	2.1	117
441	Peripheral neuropathy in multiple myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVD) therapy. <i>Blood</i> , 2013 , 121, 858	2.1	10
440	PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. <i>Blood</i> , 2013 , 122, 2331-7	2.1	255
439	Intracellular NAD+ depletion enhances bortezomib-induced anti-myeloma activity. <i>Blood</i> , 2013 , 122, 1243-55	2.1	65
438	Bone Turnover Biomarkers Are Useful In Monitoring Myeloma Bone Disease and As Early Predictor Biomarkers For Relapse Disease In Multiple Myeloma. <i>Blood</i> , 2013 , 122, 1869-1869	2.1	2
437	MM-005: A Phase 1 Trial Of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone (PVD) In Relapsed and/Or Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2013 , 122, 1969-1969	2.1	11
436	Time To Event Analyses in PANORAMA 2: A Phase 2 Study Of Panobinostat, Bortezomib, and Dexamethasone In Patients With Relapsed and Bortezomib-Refractory Multiple Myeloma. <i>Blood</i> , 2013 , 122, 1970-1970	2.1	3
435	A Phase I/II Open-Label Multicenter Study Of The Cyclin Kinase Inhibitor AT7519M Alone and In Combination With Bortezomib In Patients With Previously Treated Multiple Myeloma. <i>Blood</i> , 2013 , 122, 1976-1976	2.1	9
434	Phase I/II Trial Of Everolimus, Bortezomib and Rituximab In Relapsed Or Relapsed/Refractory Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2013 , 122, 4402-4402	2.1	3
433	Twice-Weekly Oral MLN9708 (Ixazomib Citrate), An Investigational Proteasome Inhibitor, In Combination With Lenalidomide (Len) and Dexamethasone (Dex) In Patients (Pts) With Newly Diagnosed Multiple Myeloma (MM): Final Phase 1 Results and Phase 2 Data. <i>Blood</i> , 2013 , 122, 535-535	2.1	16
432	ACY-1215, a Selective Histone Deacetylase (HDAC) 6 Inhibitor: Interim Results Of Combination Therapy With Bortezomib In Patients With Multiple Myeloma (MM). <i>Blood</i> , 2013 , 122, 759-759	2.1	14
431	New insights into the treatment of multiple myeloma with histone deacetylase inhibitors. <i>Current Pharmaceutical Design</i> , 2013 , 19, 734-44	3.1	23
430	Novel Agents in Multiple Myeloma 2013 , 215-228		
429	Antitumor Activities Of An Oral Selective HSP90 α Inhibitor, TAS-116, In Combination With Bortezomib In Multiple Myeloma. <i>Blood</i> , 2013 , 122, 4429-4429	2.1	
428	High Risk Multiple Myeloma Cases Are Identified In An MMRC Led Study By The SKY92 Gene Signature (MMprofiler). <i>Blood</i> , 2013 , 122, 1854-1854	2.1	
427	IgD and IgE variants of myeloma: valuable insights and therapeutic opportunities. <i>Oncology</i> , 2013 , 27, 803-4, 806	1.2	3
426	The Medical Research Council Myeloma IX trial: the impact on treatment paradigms. <i>European Journal of Haematology</i> , 2012 , 88, 1-7	3.6	6

425	The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib. <i>European Journal of Haematology</i> , 2012 , 88, 446-9	3.6	10
424	Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study. <i>British Journal of Haematology</i> , 2012 , 158, 472-80	4.4	49
423	Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function. <i>Blood</i> , 2012 , 119, e131-8	2.1	26
422	IMWG consensus on maintenance therapy in multiple myeloma. <i>Blood</i> , 2012 , 119, 3003-15	2.1	150
421	A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. <i>Blood</i> , 2012 , 119, 2764-7	2.1	119
420	Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells. <i>Blood</i> , 2012 , 120, 3958-67	2.1	61
419	How I treat plasma cell leukemia. <i>Blood</i> , 2012 , 120, 2376-89	2.1	93
418	Sequence analysis of β -subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone. <i>Blood</i> , 2012 , 120, 4513-6	2.1	58
417	Methyljasmonate displays in vitro and in vivo activity against multiple myeloma cells. <i>British Journal of Haematology</i> , 2012 , 159, 340-51	4.4	20
416	Blockade of XBP1 splicing by inhibition of IRE1 β s a promising therapeutic option in multiple myeloma. <i>Blood</i> , 2012 , 119, 5772-81	2.1	296
415	A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. <i>Cancer Cell</i> , 2012 , 22, 345-58	23.1	393
414	Perifosine, an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012 , 8, 623-33	5.2	66
413	Management of myeloma-associated renal dysfunction in the era of novel therapies. <i>Expert Review of Hematology</i> , 2012 , 5, 51-66; quiz 67-8	2.7	25
412	Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1960-5	2.1	167
411	Defibrotide for the treatment of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation. <i>Expert Review of Hematology</i> , 2012 , 5, 291-302	2.7	37
410	Latest advances and current challenges in the treatment of multiple myeloma. <i>Nature Reviews Clinical Oncology</i> , 2012 , 9, 135-43	18.8	165
409	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. <i>Leukemia</i> , 2012 , 26, 149-57	10.3	580
408	New proteasome inhibitors in myeloma. <i>Current Hematologic Malignancy Reports</i> , 2012 , 7, 258-66	4.2	74

407	Proteasome inhibitors in multiple myeloma: 10 years later. <i>Blood</i> , 2012 , 120, 947-59	2.1	370
406	Lenalidomide for the treatment of relapsed and refractory multiple myeloma. <i>Cancer Management and Research</i> , 2012 , 4, 253-68	3.5	26
405	Imaging features of extramedullary, relapsed, and refractory multiple myeloma involving the liver across treatment with cyclophosphamide, lenalidomide, bortezomib, and dexamethasone. <i>Journal of Clinical Oncology</i> , 2012 , 30, e175-9	2.1	9
404	Lenalidomide after stem-cell transplantation for multiple myeloma. <i>New England Journal of Medicine</i> , 2012 , 366, 1770-81	57.2	862
403	Pathological crystallization of human immunoglobulins. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 13359-61	11.1	29
402	Dual inhibition of canonical and noncanonical NF- κ B pathways demonstrates significant antitumor activities in multiple myeloma. <i>Clinical Cancer Research</i> , 2012 , 18, 4669-81	12.3	63
401	Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. <i>Blood</i> , 2012 , 119, 4375-82	2.1	335
400	Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma. <i>Molecular Cancer Therapeutics</i> , 2012 , 11, 942-51	5.8	43
399	Safety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease. <i>Therapeutic Advances in Hematology</i> , 2012 , 3, 253-65	5.5	32
398	PANORAMA 2: Panobinostat Combined with Bortezomib and Dexamethasone in Patients with Relapsed and Bortezomib-Refractory Multiple Myeloma. <i>Blood</i> , 2012 , 120, 1852-1852	2.1	4
397	A Phase 2 Study of Elotuzumab (Elo) in Combination with Lenalidomide and Low-Dose Dexamethasone (Ld) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (R/R MM): Updated Results. <i>Blood</i> , 2012 , 120, 202-202	2.1	12
396	Early Changes in Cytokines, Chemokines and Indices of Bone Metabolism in a Phase 2 Study of the Bruton Tyrosine Kinase (Btk) Inhibitor, Ibrutinib (PCI-32765) in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM). <i>Blood</i> , 2012 , 120, 4039-4039	2.1	3
395	Improvement in Clinical Benefit Parameters with Pomalidomide (POM) in Combination with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Results From a Phase 2 Study. <i>Blood</i> , 2012 , 120, 4052-4052	2.1	2
394	Treatment Outcomes with Pomalidomide (POM) in Combination with Low-Dose Dexamethasone (LoDex) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM) and Del(17p13) and/or t(4;14)(p16;q32) Cytogenetic Abnormalities Who Have Received Prior Therapy with Lenalidomide (LEN). <i>Blood</i> , 2012 , 120, 4053-4053	2.1	4
393	Pomalidomide (POM) with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Outcomes Based on Prior Treatment Exposure. <i>Blood</i> , 2012 , 120, 4070-4070	2.1	1
392	Pomalidomide (POM) with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Impact of Renal Function on Patient Outcomes. <i>Blood</i> , 2012 , 120, 4072-4072	2.1	3
391	Pomalidomide (POM) with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT): Updated Phase 2 Results and Age Subgroup Analysis. <i>Blood</i> , 2012 , 120, 450-450	2.1	8
390	Daratumumab, a CD38 Monoclonal Antibody in Patients with Multiple Myeloma - Data From a Dose-Escalation Phase I/II Study. <i>Blood</i> , 2012 , 120, 73-73	2.1	15

389	New Insights into the Treatment of Multiple Myeloma with Histone Deacetylase Inhibitors. <i>Current Pharmaceutical Design</i> , 2012 , 19, 734-744	3.1	1
388	Reprogramming Aberrant B Cell-Subsets to Improve Immune Function in Multiple Myeloma. <i>Blood</i> , 2012 , 120, 3986-3986	2.1	
387	Myeloid Derived Suppressor Cells (MDSCs) Regulate Tumor Growth, Immune Response and Regulatory T Cell (Treg) Development in the Multiple Myeloma Bone Marrow Microenvironment. <i>Blood</i> , 2012 , 120, 565-565	2.1	
386	Targeting Aminopeptidases by Tosedostat (TST) (CHR2797), Alone and with LBH589, Induces Significant Cytotoxicity Against Human Multiple Myeloma (MM) Cells. <i>Blood</i> , 2012 , 120, 1847-1847	2.1	
385	Formation of the Functional Niche in Vitro by Mimicking the Pathophysiological Features of the Bone Marrow Microenvironment in Multiple Myeloma. <i>Blood</i> , 2012 , 120, 1812-1812	2.1	
384	Cells of the Osteoblast Lineage Confer Myeloma Cell Resistance to Established and Investigational Therapeutic Agents. <i>Blood</i> , 2012 , 120, 3995-3995	2.1	
383	Multiple myeloma. <i>Annual Review of Medicine</i> , 2011 , 62, 249-64	16.8	99
382	Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1916-23	2.1	66
381	Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma. <i>Expert Review of Hematology</i> , 2011 , 4, 51-60	2.7	21
380	BET bromodomain inhibition as a therapeutic strategy to target c-Myc. <i>Cell</i> , 2011 , 146, 904-17	54.5	2045
379	Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study. <i>Lancet Oncology</i> , 2011 , 12, 263-72	20.9	72
378	Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. <i>Blood</i> , 2011 , 117, 393-402	2.1	169
377	Management of relapsed and relapsed/refractory multiple myeloma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011 , 9, 1209-16	6.4	20
376	Genetic variation associated with bortezomib-induced peripheral neuropathy. <i>Pharmacogenetics and Genomics</i> , 2011 , 21, 121-9	1.9	53
375	Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. <i>Blood</i> , 2011 , 117, 4409-19	2.1	125
374	Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. <i>Blood</i> , 2011 , 117, 4691-5	2.1	681
373	International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. <i>Blood</i> , 2011 , 117, 6063-73	2.1	234
372	Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial. <i>Blood</i> , 2011 , 118, 535-43	2.1	70

371	Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy. <i>Haematologica</i> , 2011 , 96, 1662-9	6.4	50
370	Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers. <i>British Journal of Haematology</i> , 2011 , 152, 367-79	4.4	104
369	Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications. <i>British Journal of Haematology</i> , 2011 , 152, 420-32	4.4	21
368	Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA study. <i>British Journal of Haematology</i> , 2011 , 153, 212-21	4.4	11
367	Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study. <i>British Journal of Haematology</i> , 2011 , 153, 729-40	4.4	84
366	Monoclonal antibodies in the treatment of multiple myeloma. <i>British Journal of Haematology</i> , 2011 , 154, 745-54	4.4	61
365	Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings. <i>British Journal of Haematology</i> , 2011 , 154, 755-62	4.4	17
364	Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. <i>European Journal of Haematology</i> , 2011 , 86, 23-31	3.6	99
363	A novel panel of protein biomarkers for predicting response to thalidomide-based therapy in newly diagnosed multiple myeloma patients. <i>Proteomics</i> , 2011 , 11, 1391-402	4.1	26
362	A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma. <i>American Journal of Hematology</i> , 2011 , 86, 573-8	6.9	19
361	In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. <i>Clinical Cancer Research</i> , 2011 , 17, 5311-21	12.3	256
360	Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. <i>Molecular Cancer Therapeutics</i> , 2011 , 10, 2034-42	5.8	213
359	Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myeloma. <i>Haematologica</i> , 2011 , 96, 1170-9	6.4	63
358	Treatment options for relapsed and refractory multiple myeloma. <i>Clinical Cancer Research</i> , 2011 , 17, 1264-77	12.3	103
357	A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2011 , 52, 2308-15	1.8	23
356	Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4243-9	2.1	107
355	Blockade of XBP1 Splicing by Inhibition of IRE1 β s a Promising Therapeutic Option in Multiple Myeloma. <i>Blood</i> , 2011 , 118, 133-133	2.1	2
354	A Phase I/II, Dose-Escalation Study of Daratumumab, A CD38 Mab in Patients with Multiple Myeloma [Preliminary Safety Data]. <i>Blood</i> , 2011 , 118, 1873-1873	2.1	1

353	Phase I Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2011 , 118, 1874-1874	2.1	1
352	Simulation of Clinical Outcome for Pomalidomide Plus Low-Dose Dexamethasone in Patients with Refractory Multiple Myeloma Based on Week 8 M-Protein Response. <i>Blood</i> , 2011 , 118, 1881-1881	2.1	9
351	Phase I Trial of Everolimus and Rituximab or Everolimus, Bortezomib and Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2011 , 118, 2705-2705	2.1	1
350	Final Results of the Phase II Trial of Single Agent Panobinostat (LBH589) in Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia. <i>Blood</i> , 2011 , 118, 2706-2706	2.1	1
349	Risk of Second Primary Malignancies (SPMs) Following Bortezomib (Btz)-Based Therapy: Analysis of Four Phase 3 Randomized Controlled Trials in Previously Untreated or Relapsed Multiple Myeloma (MM). <i>Blood</i> , 2011 , 118, 2933-2933	2.1	4
348	Investigational Agent MLN9708, An Oral Proteasome Inhibitor, in Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (MM): Results From the Expansion Cohorts of a Phase 1 Dose-Escalation Study. <i>Blood</i> , 2011 , 118, 301-301	2.1	5
347	Phase 1 Clinical Evaluation of Twice-Weekly Marizomib (NPI-0052), a Novel Proteasome Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM). <i>Blood</i> , 2011 , 118, 302-302	2.1	22
346	A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2011 , 118, 303-303	2.1	4
345	Biomarker Correlation with Outcomes in Patients with Relapsed or Refractory Multiple Myeloma on a Phase I Study of Everolimus in Combination with Lenalidomide,. <i>Blood</i> , 2011 , 118, 3966-3966	2.1	1
344	Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in High-Risk and/or Stage 23 Relapsed and/or Refractory Multiple Myeloma: A Retrospective Subset Analysis of the Phase 2 Study,. <i>Blood</i> , 2011 , 118, 3968-3968	2.1	1
343	Continued Overall Survival Benefit After 5 Years' Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial. <i>Blood</i> , 2011 , 118, 476-476	2.1	12
342	Phase 1/2 Study of Oral MLN9708, A Novel, Investigational Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously Untreated Multiple Myeloma (MM). <i>Blood</i> , 2011 , 118, 479-479	2.1	2
341	Defibrotide (DF) in the Treatment of Hepatic Venous Occlusive Disease (VOD) in Stem Cell Transplant (SCT) and Non-SCT Patients (Pts): Early Intervention Improves Outcome - Updated Results of a Treatment IND Expanded Access Protocol. <i>Blood</i> , 2011 , 118, 487-487	2.1	3
340	Randomized, Open Label Phase 1/2 Study of Pomalidomide (POM) Alone or in Combination with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide (LEN) and Bortezomib (BORT): Phase 2 Results. <i>Blood</i> , 2011 , 118, 634-634	2.1	5
339	Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma: Principles of Identification and Management 2011 , 95-105		1
338	Preclinical Activities of Bortezomib in MM, the Bone Marrow Microenvironment and Pharmacogenomics 2011 , 29-42		
337	Inhibition of c-Myc Expression and Function in Hematologic Malignancies. <i>Blood</i> , 2011 , 118, 1409-1409	2.1	
336	Perifosine Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezomib: Final Results of a Phase I/II Trial. <i>Blood</i> , 2011 , 118, 815-815	2.1	

335	RVD Induction Followed by Consolidation with ASCT in Patients with Newly Diagnosed Multiple Myeloma,. <i>Blood</i> , 2011 , 118, 4134-4134	2.1	
334	Mitochondrial Apoptotic Priming Measured by BH3 Profiling Regulates Clinical Response to Chemotherapy in Myeloma and Acute Lymphoblastic Leukemia and Explains Therapeutic Index. <i>Blood</i> , 2011 , 118, 1442-1442	2.1	
333	Mutational Analysis of Tumor Samples From Patients with Relapsed or Refractory Multiple Myeloma (MM) Highlights the Prevalence of RAS/RAF Pathway Activation and Demonstrates Previously Unreported Mutations in Known Cancer Genes. <i>Blood</i> , 2011 , 118, 1377-1377	2.1	
332	A Novel Acanthoic Acid Analog NPI-1342 Blocks IB Kinase and Trigger In Vitro and In Vivo cytotoxicity in Multiple Myeloma Cells. <i>Blood</i> , 2011 , 118, 1841-1841	2.1	
331	Differences in Patterns of Treatment and Outcome Among Patients with Relapsed Refractory Myeloma From United States, Europe and Asia,. <i>Blood</i> , 2011 , 118, 3989-3989	2.1	
330	Proteasome Inhibitors Sensitize Myeloma Cells to T Cell-Mediated Killing. <i>Blood</i> , 2011 , 118, 1838-1838	2.1	
329	MGUS and smoldering myeloma: the most prevalent of plasma cell dyscrasias. <i>Oncology</i> , 2011 , 25, 594, 596	1.2	1
328	Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo. <i>British Journal of Haematology</i> , 2010 , 149, 537-49	4.4	107
327	Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma. <i>British Journal of Haematology</i> , 2010 , 150, 428-37	4.4	53
326	Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study. <i>British Journal of Haematology</i> , 2010 , 150, 438-45	4.4	52
325	Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. <i>Nature Medicine</i> , 2010 , 16, 483-9	49.3	247
324	The treatment of multiple myeloma patients not eligible for asct. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2010 , 2, e2010009	3	2
323	Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1422-8	2.1	118
322	Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2010 , 116, 679-86	2.1	680
321	Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma. <i>Clinical Cancer Research</i> , 2010 , 16, 3260-9	12.3	56
320	Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial. <i>Haematologica</i> , 2010 , 95, 1144-9	6.4	37
319	Conflicts of interest, authorship, and disclosures in industry-related scientific publications. <i>Mayo Clinic Proceedings</i> , 2010 , 85, 197-9; author reply 201-4	6.2	2
318	Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4976-84	2.1	290

317	Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 157-68	2.1	406
316	Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 1005-17	2.1	196
315	Prediction of veno-occlusive disease using biomarkers of endothelial injury. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 1180-5	2.1	69
314	A new standard of care in newly diagnosed multiple myeloma. <i>Lancet, The</i> , 2010 , 376, 2043-4	36.2	
313	Towards a better understanding of treatment-related peripheral neuropathy in multiple myeloma. <i>Lancet Oncology, The</i> , 2010 , 11, 1014-6	20.9	7
312	PI3K/p110{delta} is a novel therapeutic target in multiple myeloma. <i>Blood</i> , 2010 , 116, 1460-8	2.1	157
311	A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. <i>Blood</i> , 2010 , 115, 5202-13	2.1	221
310	Kidney disease associated with plasma cell dyscrasias. <i>Blood</i> , 2010 , 116, 1397-404	2.1	40
309	Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. <i>Blood</i> , 2010 , 116, 3743-50	2.1	91
308	A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. <i>Blood</i> , 2010 , 116, 4906-15	2.1	170
307	Improving the therapeutic index in myeloma. <i>Blood</i> , 2010 , 116, 4733-4	2.1	4
306	Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma. <i>Blood</i> , 2010 , 115, 834-45	2.1	94
305	Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010 , 8 Suppl 1, S4-S12	6.4	26
304	Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. <i>Blood</i> , 2010 , 116, 3227-37	2.1	172
303	Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2259-66	2.1	352
302	The evolution and impact of therapy in multiple myeloma. <i>Medical Oncology</i> , 2010 , 27 Suppl 1, S1-6	3.6	32
301	Phase I Trial of Plerixafor and Bortezomib as a Chemosensitization Strategy In Relapsed or Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2010 , 116, 1943-1943	2.1	2
300	A Phase I Study of Vorinostat, Lenalidomide, and Dexamethasone In Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Excellent Tolerability and Promising Activity In a Heavily Pretreated Population. <i>Blood</i> , 2010 , 116, 1951-1951	2.1	4

299	A Novel SIRT1 Activator SIRT1720 Triggers In Vitro and In Vivo Cytotoxicity In Multiple Myeloma Via ATM-Dependent Mechanism. <i>Blood</i> , 2010 , 116, 3007-3007	2.1	1
298	Daratumumab Directly Induces Human Multiple Myeloma Cell Death and Acts Synergistically with Conventional and Novel Anti-Myeloma Drugs. <i>Blood</i> , 2010 , 116, 3013-3013	2.1	1
297	Updated Results of a Phase I Study of RAD001 In Combination with Lenalidomide In Patients with Relapsed or Refractory Multiple Myeloma with Pharmacodynamic and Pharmacokinetic Analysis. <i>Blood</i> , 2010 , 116, 3051-3051	2.1	3
296	Meta-Analysis of Defibrotide (DF) In the Treatment of Severe Hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF) with Comparison to a Historical Control (HC).. <i>Blood</i> , 2010 , 116, 3481-3481	2.1	5
295	Safety of Defibrotide (DF) In Stem Cell Transplant (SCT) Patients (Pts).. <i>Blood</i> , 2010 , 116, 3482-3482	2.1	3
294	The Multiple Myeloma Research Consortium (MMRC) Model: Reduced Time to Trial Activation and Improved Accrual Metrics.. <i>Blood</i> , 2010 , 116, 3803-3803	2.1	2
293	Phase II Trial of Single Agent Panobinostat (LBH589) In Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia. <i>Blood</i> , 2010 , 116, 3952-3952	2.1	6
292	Novel Three- and Four-Drug Combination Regimens of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Previously Untreated Multiple Myeloma: Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study. <i>Blood</i> , 2010 , 116, 621-621	2.1	9
291	Defibrotide (DF) In the Treatment of Severe Hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF): Results of a Treatment IND Expanded Access Protocol. <i>Blood</i> , 2010 , 116, 906-906	2.1	2
290	Elotuzumab In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed Multiple Myeloma: Interim Results of a Phase 2 Study. <i>Blood</i> , 2010 , 116, 986-986	2.1	3
289	Final Results of the Phase I/II Trial of Weekly Bortezomib In Combination with Temsirolimus (CCI-779) In Relapsed or Relapsed/Refractory Multiple Myeloma Specifically In Patients Refractory to Bortezomib. <i>Blood</i> , 2010 , 116, 990-990	2.1	5
288	Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy. <i>Core Evidence</i> , 2010 , 4, 215-45	4.7	16
287	Proteomic Profiling of Multiple Myeloma (MM) Cells Using iTRAQ and Label-Free Quantitative Proteomics for the Prediction of Complete or near Complete Response (CR/nCR) In Frontline Treatment with Lenalidomide, Bortezomib, and Dexamethasone. <i>Blood</i> , 2010 , 116, 618-618	2.1	
286	MLN4924, a Novel Investigational NEDD8 Activating Enzyme Inhibitor, Exhibits Preclinical Activity In Multiple Myeloma and Waldenstro m's Macroglobulinemia through Mechanism Distinct From Existing Proteasome Inhibitors. <i>Blood</i> , 2010 , 116, 2988-2988	2.1	1
285	An Investigational Novel Orally Bioavailable Proteasome Inhibitor MLN9708/MLN2238 Triggers Cytotoxicity In Multiple Myeloma Cells Via p21- and Caspase-8-Dependent Signaling Pathway. <i>Blood</i> , 2010 , 116, 2992-2992	2.1	
284	Anti-Myeloma Activity of Enzymatically Activated Melphalan Prodrug J1. <i>Blood</i> , 2010 , 116, 1838-1838	2.1	
283	Human Monoclonal Antibody Targeting IL-17A (AIN457) Down-Regulates MM Cell-Growth and Survival and Inhibits Osteoclast Development In Vitro and In Vivo: A Potential Novel Therapeutic Application In Myeloma. <i>Blood</i> , 2010 , 116, 456-456	2.1	
282	Hematological Testing Is Not Required with Every Dose of Bortezomib In Patients with Adequate Blood Counts at the Start of Each Cycle. <i>Blood</i> , 2010 , 116, 1963-1963	2.1	0

281	Preclinical Studies of Salinomycin In Multiple Myeloma (MM) Models: Targeting of Side Population (SP) Cells In the Context of Tumor Microenvironment Interactions.. <i>Blood</i> , 2010 , 116, 1574-1574	2.1	2
280	Compartment-Specific Bioluminescence Imaging Platform for the Open-Ended Identification of Novel Immunomodulatory Agents and High-Throughput Evaluation of Anti-Tumor Immune Function. <i>Blood</i> , 2010 , 116, 451-451	2.1	
279	Lenalidomide Enhances Multiple Myeloma Cytotoxicity Induced by a Novel Fc Domain-Engineered Anti-HM1.24 Monoclonal Antibody with Augmented NK Cell Degranulation. <i>Blood</i> , 2010 , 116, 4064-4064 ^{2.1}	2.1	
278	Elotuzumab In Combination with Bortezomib In Patients with Relapsed/Refractory Multiple Myeloma: Updated Results of a Phase 1 Study. <i>Blood</i> , 2010 , 116, 3023-3023	2.1	
277	Synergistic Enhancement of Conventional Anti-MM Drugs Efficacy with Plant Isothiocyanates: Therapeutic Implications. <i>Blood</i> , 2010 , 116, 5016-5016	2.1	
276	Tailoring treatment for multiple myeloma patients with relapsed and refractory disease. <i>Oncology</i> , 2010 , 24, 22-9	1.2	9
275	Novel therapies in the treatment of multiple myeloma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009 , 7, 947-60	6.4	28
274	Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenström's Macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2009 , 50, 694-702	1.8	26
273	Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5713-9	2.1	141
272	Reply to C.A. Dasanu et al. <i>Journal of Clinical Oncology</i> , 2009 , 27, 2294-2296	2.1	2
271	Use of defibrotide in the treatment and prevention of veno-occlusive disease. <i>Expert Review of Hematology</i> , 2009 , 2, 365-76	2.7	12
270	Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib. <i>Clinical Cancer Research</i> , 2009 , 15, 7153-60	12.3	60
269	Emerging therapies for multiple myeloma. <i>Expert Opinion on Emerging Drugs</i> , 2009 , 14, 99-127	3.5	40
268	Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3518-25	2.1	213
267	VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study. <i>Journal of Clinical Oncology</i> , 2009 , 27, 6086-93	2.1	131
266	Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. <i>Blood</i> , 2009 , 114, 1046-52	2.1	285
265	Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias. <i>Clinical Cancer Research</i> , 2009 , 15, 1210-21	12.3	41
264	The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. <i>Clinical Cancer Research</i> , 2009 , 15, 4028-37	12.3	178

263	Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. <i>Cancer Cell</i> , 2009 , 16, 309-23	23.1	197
262	Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. <i>British Journal of Haematology</i> , 2009 , 144, 895-903	4.4	252
261	Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. <i>British Journal of Haematology</i> , 2009 , 146, 164-70	4.4	71
260	Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma. <i>British Journal of Haematology</i> , 2009 , 147, 531-4	4.4	26
259	In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465. <i>British Journal of Haematology</i> , 2009 , 147, 672-6	4.4	23
258	Novel Combination Therapies for the Treatment of Relapsed/Refractory Multiple Myeloma: Current Phase I/II Combinations. <i>Clinical Lymphoma and Myeloma</i> , 2009 , 9, S40-S42		
257	Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib. <i>Seminars in Hematology</i> , 2009 , 46, 166-75	3.8	52
256	Multiple myeloma. <i>Lancet, The</i> , 2009 , 374, 324-39	36.2	605
255	The fibrinolytic mechanism of defibrotide: effect of defibrotide on plasmin activity. <i>Blood Coagulation and Fibrinolysis</i> , 2009 , 20, 627-34	1	32
254	Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications. <i>Blood</i> , 2009 , 113, 5228-36	2.1	62
253	Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. <i>Blood</i> , 2009 , 114, 772-8	2.1	130
252	How I treat multiple myeloma in younger patients. <i>Blood</i> , 2009 , 114, 5436-43	2.1	116
251	Bortezomib in the management of multiple myeloma. <i>Cancer Management and Research</i> , 2009 , 1, 107-17, 3, 5		5
250	Novel Three and Four Drug Combinations of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Newly Diagnosed Multiple Myeloma: Encouraging Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study.. <i>Blood</i> , 2009 , 114, 127-127	2.1	11
249	Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Updated Results of Phase I/II MMRC Trial.. <i>Blood</i> , 2009 , 114, 132-132	2.1	5
248	Lack of Response to Vaccination in MGUS and Stable Myeloma.. <i>Blood</i> , 2009 , 114, 1852-1852	2.1	3
247	Tanespimycin + Bortezomib in Relapsed/Refractory Myeloma Patients: Results From the Time-2 Study.. <i>Blood</i> , 2009 , 114, 1871-1871	2.1	3
246	Natural History of Multiple Myeloma Relapsing After Therapy with IMiDs and Bortezomib: A Multicenter International Myeloma Working Group Study.. <i>Blood</i> , 2009 , 114, 2878-2878	2.1	10

245	Tanespimycin + Bortezomib Demonstrates Safety, Activity, and Effective Target Inhibition in Relapsed/Refractory Myeloma Patients: Updated Results of a Phase 1/2 Study.. <i>Blood</i> , 2009 , 114, 2890-2890	2.1	6
244	Defibrotide (DF) in the Treatment of Severe Hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF) Following Stem Cell Transplantation (SCT): Results of a Phase 3 Study Utilizing a Historical Control.. <i>Blood</i> , 2009 , 114, 654-654	2.1	11
243	Microenvironment-Dependent Synthetic Lethality: Implications for Tumor Pathophysiology and Anti-Cancer Drug Discovery.. <i>Blood</i> , 2009 , 114, 1722-1722	2.1	
242	Immunomodulatory EFFECTS of Lenalidomide and Pomalidomide ON INTERACTION of TUMOR and BONE MARROW Accessory CELLS IN MULTIPLE MYELOMA.. <i>Blood</i> , 2009 , 114, 950-950	2.1	
241	Whole Genome Paired End Sequencing Identifies Genomic Evolution in Myeloma.. <i>Blood</i> , 2009 , 114, 2846-2846	2.1	1
240	A NOVEL Aurora A Kinase INHIBITOR MLN8237 Induces Cytotoxicity and CELL Cycle Arrest IN MULTIPLE MYELOMA.. <i>Blood</i> , 2009 , 114, 3830-3830	2.1	
239	PR-924, a Selective Inhibitor of the Immunoproteasome Subunit LMP-7 Blocks Multiple Myeloma Cell Growth Both in Vitro and In Vivo.. <i>Blood</i> , 2009 , 114, 612-612	2.1	
238	Fatty acid synthase is a novel therapeutic target in multiple myeloma. <i>British Journal of Haematology</i> , 2008 , 141, 659-71	4.4	27
237	The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. <i>British Journal of Haematology</i> , 2008 , 143, 46-53	4.4	91
236	Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma. <i>British Journal of Haematology</i> , 2008 , 143, 222-9	4.4	81
235	Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. <i>British Journal of Haematology</i> , 2008 , 143, 537-40	4.4	74
234	Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study. <i>British Journal of Haematology</i> , 2008 , 143, 511-9	4.4	49
233	Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. <i>New England Journal of Medicine</i> , 2008 , 359, 906-17	57.2	1580
232	Bortezomib in the front-line treatment of multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2008 , 8, 1053-72	3.4	73
231	Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. <i>Leukemia and Lymphoma</i> , 2008 , 49, 502-7	1.8	174
230	Re: When you look matters: the effect of assessment schedule on progression-free survival. <i>Journal of the National Cancer Institute</i> , 2008 , 100, 373	9.3	7
229	Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment. <i>Clinical Cancer Research</i> , 2008 , 14, 865-74	12.3	51
228	Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo. <i>Cancer Research</i> , 2008 , 68, 5216-25	9.6	79

227	Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. <i>Journal of Clinical Oncology</i> , 2008 , 26, 3196-203	2.1	139
226	Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. <i>Journal of Clinical Oncology</i> , 2008 , 26, 4784-90	2.1	227
225	Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw. <i>Clinical Cancer Research</i> , 2008 , 14, 2387-95	12.3	114
224	Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. <i>Blood</i> , 2008 , 111, 1654-64	2.1	174
223	Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. <i>Blood</i> , 2008 , 112, 1329-37	2.1	366
222	Angiogenesis alteration by defibrotide: implications for its mechanism of action in severe hepatic veno-occlusive disease. <i>Blood</i> , 2008 , 112, 4343-52	2.1	52
221	Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. <i>Blood</i> , 2008 , 112, 4425-31	2.1	139
220	Advances in the treatment of monoclonal gammopathies: The emerging role of targeted therapy in plasma cell dyscrasias. <i>Biologics: Targets and Therapy</i> , 2008 , 2, 419-31	4.3	3
219	The monoclonal antibody nBT062 conjugated to maytansinoids has potent and selective cytotoxicity against CD138 positive multiple myeloma cells in vitro and in vivo. <i>Nature Precedings</i> , 2008 ,		2
218	A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma. <i>Therapeutics and Clinical Risk Management</i> , 2008 , 4, 129-36	2.8	28
217	From the bench to the bedside: emerging new treatments in multiple myeloma. <i>Targeted Oncology</i> , 2008 , 3, 19-29	4.8	
216	Phase II Trial of the mTOR Inhibitor RAD001 in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: The Dana Farber Cancer Institute Experience.. <i>Blood</i> , 2008 , 112, 1011-1011	2.1	1
215	A Novel Aurora-a Kinase Inhibitor MLN8237 Induces Cytotoxicity and Cell Cycle Arrest in Experimental Multiple Myeloma Models.. <i>Blood</i> , 2008 , 112, 1719-1719	2.1	2
214	Combination of a Novel Proteasome Inhibitor NPI-0052 and Lenalidomide Trigger in Vivo Synergistic Cytotoxicity in Multiple Myeloma. <i>Blood</i> , 2008 , 112, 3662-3662	2.1	1
213	Phase I Results of Perifosine (KRX-0401) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (MM). <i>Blood</i> , 2008 , 112, 3691-3691	2.1	10
212	Phase I Trial of CCI-779 (Temsirolimus) and Weekly Bortezomib in Relapsed and/or Refractory Multiple Myeloma. <i>Blood</i> , 2008 , 112, 3696-3696	2.1	10
211	Final Results of a Phase II Trial with Plitidepsin (Aplidin) Alone and in Combination with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2008 , 112, 3700-3700	2.1	4
210	Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia. <i>Blood</i> , 2008 , 112, 832-832	2.1	6

209	Lenalidomide, Bortezomib, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Encouraging Efficacy in High Risk Groups with Updated Results of a Phase I/II Study. <i>Blood</i> , 2008 , 112, 92-92	2.1	21
208	Safety and Efficacy of Novel Combination Therapy with Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide in Newly Diagnosed Multiple Myeloma: Initial Results from the Phase I/II Multi-Center EVOLUTION Study. <i>Blood</i> , 2008 , 112, 93-93	2.1	12
207	The Role of Heat Shock Protein 90 as a Therapeutic Target for Multiple Myeloma 2008 , 291-308		
206	The Role of Bortezomib in the Treatment of Relapsed and Refractory Multiple Myeloma 2008 , 239-252		
205	Hepatic Veno-Occlusive Disease 2008 , 467-493		
204	Sulforaphane and PEITC Augment Activity of Conventional and Novel Anti-Myeloma Drugs. <i>Blood</i> , 2008 , 112, 2648-2648	2.1	
203	Immunomodulatory Effects of Lenalidomide and Bortezomib on Bone Marrow Stroma Cell and CD4 T Cell Interaction in Multiple Myeloma.. <i>Blood</i> , 2008 , 112, 1690-1690	2.1	
202	The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Potent and Selective Cytotoxicity against CD138 Positive Multiple Myeloma Cells in Vitro and in Vivo.. <i>Blood</i> , 2008 , 112, 1716-1716 ³	2.1	3
201	Compartment-Specific Bioluminescence Imaging (CS-BLI) High- Throughput Assays Provide Comparative Insights into the Impact of Osteoclasts Vs. Stromal Cells on Activity of Anti-Myeloma Therapeutics. <i>Blood</i> , 2008 , 112, 219-219	2.1	
200	TH17 Pathway Promotes Tumor Cell Growth and Suppresses Immune Function in Myeloma: Potential for Therapeutic Application. <i>Blood</i> , 2008 , 112, 2737-2737	2.1	
199	Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series. <i>Clinical Advances in Hematology and Oncology</i> , 2008 , 6, 755-60	0.6	41
198	From the bench to the bedside: emerging new treatments in multiple myeloma. <i>Best Practice and Research in Clinical Haematology</i> , 2007 , 20, 797-816	4	55
197	Toward a new therapeutic backbone in myeloma. <i>Blood</i> , 2007 , 109, 2672-2673	2.1	6
196	Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients. <i>American Journal of Hematology</i> , 2007 , 82, 831-3	6.9	30
195	Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment. <i>Journal of Cellular Biochemistry</i> , 2007 , 101, 950-68	4.6	77
194	Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. <i>Nature Reviews Cancer</i> , 2007 , 7, 585-98	30.2	699
193	Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. <i>British Journal of Haematology</i> , 2007 , 137, 429-35	4.4	103
192	Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. <i>British Journal of Haematology</i> , 2007 , 138, 783-91	4.4	94

191	Emerging drugs in multiple myeloma. <i>Expert Opinion on Emerging Drugs</i> , 2007 , 12, 155-63	3.5	9
190	Does maintenance therapy with thalidomide benefit patients with multiple myeloma?. <i>Nature Clinical Practice Oncology</i> , 2007 , 4, 394-5		5
189	Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: review and update on the use of defibrotide. <i>Seminars in Thrombosis and Hemostasis</i> , 2007 , 33, 373-88	5.1	36
188	New drugs for myeloma. <i>Oncologist</i> , 2007 , 12, 664-89	5.5	138
187	Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma. <i>Clinical Cancer Research</i> , 2007 , 13, 6162-7	12.3	58
186	The treatment of relapsed and refractory multiple myeloma. <i>Hematology American Society of Hematology Education Program</i> , 2007 , 2007, 317-23	2.9	45
185	Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. <i>Blood</i> , 2007 , 110, 1656-63	6.3	103
184	Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. <i>Blood</i> , 2007 , 110, 3557-60	2.1	443
183	Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. <i>Blood</i> , 2007 , 109, 3177-88	2.1	314
182	Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. <i>Blood</i> , 2007 , 109, 2604-6	2.1	215
181	The emerging role of novel therapies for the treatment of relapsed myeloma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2007 , 5, 149-62	6.4	56
180	Novel therapies in myeloma. <i>Current Opinion in Hematology</i> , 2007 , 14, 609-15	3.2	14
179	High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials. <i>Biology of Blood and Marrow Transplantation</i> , 2007 , 13, 183-96	2.1	168
178	Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2007 , 7, 551-66	3.4	11
177	Management of relapsed and relapsed refractory myeloma. <i>Hematology/Oncology Clinics of North America</i> , 2007 , 21, 1175-215, x	3	4
176	The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies. <i>Hematology/Oncology Clinics of North America</i> , 2007 , 21, 1007-34, vii-viii	3	101
175	Multi-Center Phase II Study of Perifosine (KRX-0401) Alone and in Combination with Dexamethasone (dex) for Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Promising Activity as Combination Therapy with Manageable Toxicity.. <i>Blood</i> , 2007 , 110, 1164-1164	2.1	14
174	Tanespimycin (T) + Bortezomib (BZ) in Multiple Myeloma (MM): Confirmation of the Recommended Dose Using a Novel Formulation.. <i>Blood</i> , 2007 , 110, 1165-1165	2.1	14

173	Phase I/II Report from a Multicenter Trial of Perifosine (KRX-0401) + Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma Previously Treated with Bortezomib.. <i>Blood</i> , 2007 , 110, 1170-1170	2.1	9
172	Final Results of a Phase I Trial of Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Patients with Advanced Multiple Myeloma.. <i>Blood</i> , 2007 , 110, 1179-1179	2.1	9
171	Anti-Myeloma Activity of Selective PI-3K/PDK/mTOR Inhibitor BEZ235.. <i>Blood</i> , 2007 , 110, 1185-1185	2.1	2
170	Phase I Study of Vaccination with Dendritic Cell Myeloma Fusions.. <i>Blood</i> , 2007 , 110, 284-284	2.1	1
169	Phase II Trial of Perifosine (KRX-0401) in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.. <i>Blood</i> , 2007 , 110, 4493-4493	2.1	1
168	Phase II Trial of the Oral mTOR Inhibitor RAD001 (Everolimus) in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.. <i>Blood</i> , 2007 , 110, 4496-4496	2.1	2
167	Novel Therapeutic Options for the Treatment of Relapsed and Relapsed, Refractory Myeloma. <i>Translational Medicine Series</i> , 2007 , 169-196		
166	Activity of CDK1/2 Inhibitor LCQ195 Against Multiple Myeloma Cells.. <i>Blood</i> , 2007 , 110, 1519-1519	2.1	2
165	Combination of Proteasome Inhibitors Bortezomib and NPI-0052 Trigger In Vivo Synergistic Cytotoxicity in Multiple Myeloma.. <i>Blood</i> , 2007 , 110, 2524-2524	2.1	
164	Plasmacytoid Dendritic Cells Induce Growth and Survival of Multiple Myeloma Cells: Therapeutic Application.. <i>Blood</i> , 2007 , 110, 3507-3507	2.1	
163	Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.. <i>Blood</i> , 2007 , 110, 4494-4494	2.1	
162	In Vitro and In Vivo Anti-Myeloma Activity of PRLX, an Orally-Bioavailable Agent Against Cells with Constitutive Activation of Ras or Its Downstream Pathway.. <i>Blood</i> , 2007 , 110, 540-540	2.1	1
161	Low Levels of Circulating CS1, a Newly Identified Multiple Myeloma (MM) Antigen for a Novel Humanized HuLuc63 Monoclonal Antibody, Is Detected in MM Patient Sera and Correlates with Active Disease.. <i>Blood</i> , 2007 , 110, 1509-1509	2.1	1
160	Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial. <i>Cancer</i> , 2006 , 106, 1316-9	6.2	116
159	Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3113-20	2.1	529
158	Recent advances in the treatment of Multiple Myeloma. <i>Current Pharmaceutical Biotechnology</i> , 2006 , 7, 381-93	2.4	13
157	MLN120B, a novel I κ B kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. <i>Clinical Cancer Research</i> , 2006 , 12, 5887-94	12.3	118
156	Lenalidomide in multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2006 , 6, 1165-73	3.4	42

155	Can thalidomide improve outcome in patients with multiple myeloma?. <i>Nature Clinical Practice Oncology</i> , 2006 , 3, 590-1		3
154	Management Strategies for Relapsed Multiple Myeloma. <i>American Journal of Cancer</i> , 2006 , 5, 393-409		1
153	Emerging Therapies for Multiple Myeloma. <i>American Journal of Cancer</i> , 2006 , 5, 141-153		2
152	Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. <i>JAMA - Journal of the American Medical Association</i> , 2006 , 296, 2558-60	26.8	107
151	Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. <i>Cancer Research</i> , 2006 , 66, 6675-82	9.6	187
150	The emerging role of novel therapeutic agents in the management of patients with multiple myeloma. <i>Community Oncology</i> , 2006 , 3, 575-582		
149	Bortezomib-induced tumor lysis syndrome in multiple myeloma. <i>Clinical Lymphoma and Myeloma</i> , 2006 , 7, 233-5		36
148	Bortezomib: proteasome inhibition as an effective anticancer therapy. <i>Annual Review of Medicine</i> , 2006 , 57, 33-47	16.8	289
147	Defibrotide, a polydisperse mixture of single-stranded phosphodiester oligonucleotides with lifesaving activity in severe hepatic veno-occlusive disease: clinical outcomes and potential mechanisms of action. <i>Oligonucleotides</i> , 2006 , 16, 105-14		36
146	The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. <i>European Journal of Cancer</i> , 2006 , 42, 1564-73	4.4	171
145	Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. <i>Blood</i> , 2006 , 107, 4053-62	2.1	360
144	A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. <i>Blood</i> , 2006 , 108, 3458-64	2.1	446
143	Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma. <i>Current Opinion in Oncology</i> , 2006 , 18, 598-608	4	29
142	Proteasome inhibition as a new therapeutic principle in hematological malignancies. <i>Current Drug Targets</i> , 2006 , 7, 1341-7	2.9	38
141	FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma. <i>British Journal of Haematology</i> , 2006 , 132, 698-704	4.4	3
140	Antimyeloma activity of heat shock protein-90 inhibition. <i>Blood</i> , 2006 , 107, 1092-100	2.1	249
139	Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma. <i>British Journal of Haematology</i> , 2006 , 132, 385-97	4.4	64
138	Inhibition of ERK1/2 Activity by the MEK1/2 Inhibitor AZD6244 (ARRY-142886) Induces Human Multiple Myeloma Cell Apoptosis in the Bone Marrow Microenvironment: A New Therapeutic Strategy for MM.. <i>Blood</i> , 2006 , 108, 3460-3460	2.1	1

137	Anti-Myeloma Activity of the Small-Molecule Aurora Kinase Inhibitor VE465.. <i>Blood</i> , 2006 , 108, 3468-3468.1	2
136	Lenalidomide and Bortezomib Inhibit Osteoclast Differentiation and Activation in Multiple Myeloma: Clinical Implications.. <i>Blood</i> , 2006 , 108, 3485-3485	2.1 2
135	Utility of Bortezomib Retreatment for Patients with Relapsed Multiple Myeloma.. <i>Blood</i> , 2006 , 108, 3532-3532.6	
134	A Multicenter Phase II Study of Perifosine (KRX-0401) Alone and in Combination with Dexamethasone (Dex) For Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM).. <i>Blood</i> , 2006 , 108, 3582-3582	2.1 5
133	Lenalidomide Plus Bortezomib (Rev-Vel) in Relapsed and/or Refractory Multiple Myeloma (MM): Final Results of a Multicenter Phase 1 Trial.. <i>Blood</i> , 2006 , 108, 405-405	2.1 24
132	A Multicenter Phase 1 Clinical Trial of Tanespimycin (KOS-953) + Bortezomib (BZ): Encouraging Activity and Manageable Toxicity in Heavily Pre-Treated Patients with Relapsed Refractory Multiple Myeloma (MM).. <i>Blood</i> , 2006 , 108, 406-406	2.1 19
131	Vaccination with Dendritic Cell Myeloma Fusions Alone or in Conjunction with Stem Cell Transplantation for Patients with Multiple Myeloma.. <i>Blood</i> , 2006 , 108, 3080-3080	2.1
130	Distinct Dynamic Profiles for NPI-0052-And Bortezomib-Induced Apoptosis in Multiple Myeloma.. <i>Blood</i> , 2006 , 108, 3396-3396	2.1
129	Clinical, Radiographic, and Biomarker Characterization of Multiple Myeloma Patients with Bisphosphonate Associated Osteonecrosis of the Jaw.. <i>Blood</i> , 2006 , 108, 3591-3591	2.1
128	The BAFF Inhibitor AMG523 Blocks Adhesion and Survival of Human Multiple Myeloma Cells in the Bone Marrow Microenvironment: Clinical Implication.. <i>Blood</i> , 2006 , 108, 3452-3452	2.1 1
127	Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. <i>Haematologica</i> , 2006 , 91, 929-34	6.4 112
126	Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma. <i>Clinical Advances in Hematology and Oncology</i> , 2006 , 4, 1; discussion 8; suppl 13	0.6 4
125	Optimizing bortezomib treatment in patients with relapsed multiple myeloma. <i>Clinical Advances in Hematology and Oncology</i> , 2006 , 4, 4-5; discussion 8; suppl 13	0.6 21
124	Proteasome Inhibition in the Treatment of Cancer. <i>Cell Cycle</i> , 2005 , 4, 289-295	4.6 77
123	Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide. <i>Seminars in Hematology</i> , 2005 , 42, S9-15	3.8 61
122	Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. <i>New England Journal of Medicine</i> , 2005 , 352, 2487-98	57.2 2097
121	Emerging trends in the clinical use of bortezomib in multiple myeloma. <i>Clinical Lymphoma and Myeloma</i> , 2005 , 6, 84-8	6
120	Proteasome inhibition as a novel therapeutic target in human cancer. <i>Journal of Clinical Oncology</i> , 2005 , 23, 630-9	2.1 471

119	Novel biological therapies for the treatment of multiple myeloma. <i>Best Practice and Research in Clinical Haematology</i> , 2005 , 18, 619-34	4	40
118	Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis. <i>Blood</i> , 2005 , 106, 1794-800	2.1	157
117	Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo. <i>Blood</i> , 2005 , 105, 4470-6	2.1	54
116	Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. <i>British Journal of Haematology</i> , 2005 , 128, 192-203	4.4	265
115	Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. <i>British Journal of Haematology</i> , 2005 , 131, 71-3	4.4	169
114	Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors. <i>Oncogene</i> , 2005 , 24, 3121-9	8.9	39
113	A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. <i>Cancer Cell</i> , 2005 , 8, 407-19	23.1	611
112	Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impaired renal function. <i>Cancer</i> , 2005 , 103, 1195-200	6.2	199
111	Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. <i>Cancer</i> , 2005 , 104, 2141-8	6.2	91
110	Proteasome inhibition as an anticancer target. <i>Nature Reviews Drug Discovery</i> , 2005 , 4, 698-698	62	
109	Identification and validation of novel therapeutic targets for multiple myeloma. <i>Journal of Clinical Oncology</i> , 2005 , 23, 6345-50	2.1	65
108	Proteasome inhibitor therapy in multiple myeloma. <i>Molecular Cancer Therapeutics</i> , 2005 , 4, 686-92	5.8	142
107	Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. <i>Cancer Research</i> , 2005 , 65, 5898-906	9.6	131
106	Bortezomib: proteasome inhibition as an effective anticancer therapy. <i>Future Oncology</i> , 2005 , 1, 161-71	3.4	30
105	Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. <i>Cancer Research</i> , 2005 , 65, 11712-20	9.6	149
104	FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance. <i>Cancer Research</i> , 2005 , 65, 7478-84	9.6	86
103	Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005 , 102, 8567-72	11.1	526
102	Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. <i>Blood</i> , 2005 , 106, 3777-84	2.1	278

101	Proteasome inhibition as a therapeutic strategy for hematologic malignancies. <i>Expert Review of Anticancer Therapy</i> , 2005 , 5, 465-76	3.4	11
100	Plasma cell problems: Case 1. Disseminated cutaneous plasmacytomas treated with total skin electron radiotherapy. <i>Journal of Clinical Oncology</i> , 2005 , 23, 3138-40	2.1	8
99	Targeting Bcl-2 as Therapy for Multiple Myeloma.. <i>Blood</i> , 2005 , 106, 109-109	2.1	5
98	A Multicenter, Single-Arm, Open-Label Study To Evaluate the Efficacy and Safety of Single-Agent Lenalidomide in Patients with Relapsed and Refractory Multiple Myeloma; Preliminary Results.. <i>Blood</i> , 2005 , 106, 1565-1565	2.1	20
97	Dasatinib (BMS-354825): A Multi-Targeted Kinase Inhibitor with Activity Against Multiple Myeloma.. <i>Blood</i> , 2005 , 106, 1571-1571	2.1	2
96	PKC412 Is a Multi-Targeting Kinase Inhibitor with Activity Against Multiple Myeloma In Vitro and In Vivo.. <i>Blood</i> , 2005 , 106, 247-247	2.1	3
95	Bortezomib Continues Demonstrates Superior Efficacy Compared with High-Dose Dexamethasone in Relapsed Multiple Myeloma: Updated Results of the APEX Trail.. <i>Blood</i> , 2005 , 106, 2547-2547	2.1	21
94	The Role of B Cell-Activating Factor (BAFF) in the Biology of Multiple Myeloma (MM).. <i>Blood</i> , 2005 , 106, 3380-3380	2.1	1
93	CD27-Mediated Apoptosis Is Dependent on Siva-Induced Caspase Activation in Human Multiple Myeloma.. <i>Blood</i> , 2005 , 106, 3398-3398	2.1	0
92	A Phase 1 Trial of Lenalidomide (REVLIMID [®]) with Bortezomib (VELCADE [®]) in Relapsed and Refractory Multiple Myeloma.. <i>Blood</i> , 2005 , 106, 365-365	2.1	12
91	Expression and Modulation of Carbohydrate-Binding Protein Galectin-3 in Multiple Myeloma Cells by Combined Treatment with GCS-100 and Dexamethasone.. <i>Blood</i> , 2005 , 106, 4447-4447	2.1	1
90	Chromosomal Deletions and Amplifications in Multiple Myeloma Detected by 500K Single Nucleotide Polymorphism Array Analysis.. <i>Blood</i> , 2005 , 106, 1551-1551	2.1	
89	Immunomodulatory Drug Lenalidomide (CC-5013, IMiD3) Augments Anti-CD40 SGN-40-Induced Cytotoxicity in Human Multiple Myeloma: Clinical Implications.. <i>Blood</i> , 2005 , 106, 5150-5150	2.1	
88	Role of BAFF in Adhesion and Growth of Human Multiple Myeloma Cells in the Bone Marrow Microenvironment.. <i>Blood</i> , 2005 , 106, 627-627	2.1	
87	Proteasome inhibitors as therapeutics. <i>Essays in Biochemistry</i> , 2005 , 41, 205-218	7.4	6
86	Proteasome inhibition in the treatment of cancer. <i>Cell Cycle</i> , 2005 , 4, 290-6	4.6	40
85	New therapies for the treatment of multiple myeloma. <i>Clinical Advances in Hematology and Oncology</i> , 2005 , 3, 345-6	0.6	2
84	New treatments for multiple myeloma. <i>Oncology</i> , 2005 , 19, 1781-92; discussion 1792, 1795-7	1.2	19

83	Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma. <i>Cancer Research</i> , 2004 , 64, 8746-53	9.6	28
82	Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment. <i>Clinical Cancer Research</i> , 2004 , 10, 7540-6	12.3	93
81	Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. <i>Cancer Research</i> , 2004 , 64, 2846-52	9.6	110
80	Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib. <i>Cancer Research</i> , 2004 , 64, 7500-6	9.6	84
79	Multiple myeloma. <i>Hematology American Society of Hematology Education Program</i> , 2004 , 2004, 237-56	2.9	71
78	Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma. <i>British Journal of Haematology</i> , 2004 , 125, 343-52	4.4	64
77	p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. <i>Oncogene</i> , 2004 , 23, 8766-76	8.9	112
76	An update of novel therapeutic approaches for multiple myeloma. <i>Current Treatment Options in Oncology</i> , 2004 , 5, 227-38	5.3	9
75	Proteasome inhibition in hematologic malignancies. <i>Annals of Medicine</i> , 2004 , 36, 304-14	1.4	53
74	Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 38-2004. A 40-year-old man with a large tumor of the skull. <i>New England Journal of Medicine</i> , 2004 , 351, 2637-45	57.2	9
73	Proteasome inhibition. <i>American Journal of Cancer</i> , 2004 , 3, 271-279		
72	Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. <i>Mayo Clinic Proceedings</i> , 2004 , 79, 875-82	6.2	106
71	A multiagent strategy to decrease regimen-related toxicity in children undergoing allogeneic hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2004 , 10, 635-44	2.1	36
70	A review of the proteasome inhibitor bortezomib in multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , 2004 , 5, 1321-31	3.9	40
69	Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. <i>Blood</i> , 2004 , 103, 1787-90	2.1	230
68	The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance. <i>Blood</i> , 2004 , 103, 3158-66	2.1	106
67	GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment. <i>Blood</i> , 2004 , 103, 3474-9	2.1	79
66	Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells. <i>Blood</i> , 2004 , 104, 2458-66	2.1	70

65	Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. <i>Blood</i> , 2004 , 104, 4188-93	2.1	167
64	Phase I Clinical Trial of Oral Administration of the Histone Deacetylase (HDAC) Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) in Patients with Relapsed/Refractory Multiple Myeloma (MM).. <i>Blood</i> , 2004 , 104, 1503-1503	2.1	7
63	IPI-504: A Novel hsp90 Inhibitor with In Vitro and In Vivo Anti-Tumor Activity.. <i>Blood</i> , 2004 , 104, 2403-2403	2.1	3
62	Anti-Tumor Activity of KOS-953, a Cremophor-Based Formulation of the hsp90 Inhibitor 17-AAG.. <i>Blood</i> , 2004 , 104, 2404-2404	2.1	3
61	A Novel Orally Available Proteasome Inhibitor NPI-0052 Induces Killing in Multiple Myeloma (MM) Cells Resistant to Conventional and Bortezomib Therapies.. <i>Blood</i> , 2004 , 104, 2405-2405	2.1	2
60	Mitochondria and Caspase-Independent Cell-Death Triggered by GCS-100, a Novel Carbohydrate-Based Therapeutic in Multiple Myeloma (MM) Cells.. <i>Blood</i> , 2004 , 104, 2456-2456	2.1	1
59	Defibrotide (DF) Targets Tumor-Microenvironmental Interactions and Sensitizes Multiple Myeloma and Solid Tumor Cells to Cytotoxic Chemotherapeutics.. <i>Blood</i> , 2004 , 104, 286-286	2.1	5
58	Phase II Trial of Single Agent Bortezomib (VELCADE®) in Patients with Previously Untreated Multiple Myeloma (MM).. <i>Blood</i> , 2004 , 104, 336-336	2.1	28
57	Dendritic Cell Myeloma Fusions Stimulate Anti-Tumor Immunity: Results from Pre-Clinical Studies and a Clinical Trial.. <i>Blood</i> , 2004 , 104, 751-751	2.1	2
56	Hepatic Venous Occlusive Disease 2004 , 297-314		
55	Enhanced Cytotoxicity of Monoclonal Antibody SGN-40 and Immunomodulatory Drug IMiD3 Against Human Multiple Myeloma.. <i>Blood</i> , 2004 , 104, 1498-1498	2.1	
54	Atiprimod (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) Inhibits Myeloma in Vivo.. <i>Blood</i> , 2004 , 104, 2401-2401	2.1	
53	JNK Activation and Fas Up-Regulation Precede Proteasomal Degradation of Topoisomerase I in SN38-Mediated Cytotoxicity Against Multiple Myeloma.. <i>Blood</i> , 2004 , 104, 3413-3413	2.1	3
52	TGF- β Receptor I Kinase Inhibitor Downregulates Cytokine Secretion and Multiple Myeloma Cell Growth in the Bone Marrow Microenvironment.. <i>Blood</i> , 2004 , 104, 2355-2355	2.1	1
51	Bortezomib Targets Multiple Myeloma Endothelial Cells.. <i>Blood</i> , 2004 , 104, 4903-4903	2.1	
50	A phase 2 study of bortezomib in relapsed, refractory myeloma. <i>New England Journal of Medicine</i> , 2003 , 348, 2609-17	57.2	2196
49	Hepatic veno-occlusive disease: pathogenesis, diagnosis and treatment. <i>Current Opinion in Hematology</i> , 2003 , 10, 451-62	3.2	102
48	The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. <i>Blood</i> , 2003 , 101, 2377-80	2.1	631

47	Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. <i>Blood</i> , 2003 , 101, 703-5	2.1	101
46	Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. <i>Blood</i> , 2003 , 101, 1530-4	2.1	488
45	Molecular sequelae of histone deacetylase inhibition in human malignant B cells. <i>Blood</i> , 2003 , 101, 4055-62	2.1	274
44	NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. <i>Blood</i> , 2003 , 102, 2615-22	2.1	207
43	Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. <i>Blood</i> , 2003 , 102, 1578-82	2.1	270
42	Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. <i>Cancer Control</i> , 2003 , 10, 361-9	2.1	237
41	Hemostatic complications of hematopoietic stem cell transplantation: from hemorrhage to microangiopathies and VOD. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2003 , 33 Suppl 1, 50-3		4
40	Novel biologically based therapies for Waldenstrom's macroglobulinemia. <i>Seminars in Oncology</i> , 2003 , 30, 309-12	5.3	39
39	Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells. <i>British Journal of Haematology</i> , 2003 , 121, 592-6	4.4	39
38	Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. <i>Oncogene</i> , 2003 , 22, 8386-93	8.9	151
37	Clinical update: proteasome inhibitors in hematologic malignancies. <i>Cancer Treatment Reviews</i> , 2003 , 29 Suppl 1, 33-9	14	75
36	Novel strategies in the treatment of relapsed/refractory multiple myeloma. From the Multiple Myeloma Research Foundation. <i>Oncology</i> , 2003 , 17, 1063-5	1.2	2
35	Bortezomib: a novel therapy approved for multiple myeloma. <i>Clinical Advances in Hematology and Oncology</i> , 2003 , 1, 596-600	0.6	45
34	Novel biologically based therapies for multiple myeloma. <i>International Journal of Hematology</i> , 2002 , 76 Suppl 1, 340-1	2.2	8
33	Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays. <i>Oncogene</i> , 2002 , 21, 1346-58	8.9	157
32	Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. <i>Oncogene</i> , 2002 , 21, 5673-83	8.9	423
31	Molecular sequelae of proteasome inhibition in human multiple myeloma cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002 , 99, 14374-9	11.1	630
30	Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. <i>Blood</i> , 2002 , 99, 4079-86	2.1	341

29	2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells. <i>Blood</i> , 2002 , 100, 2187-94	2.1	102
28	Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. <i>Blood</i> , 2002 , 100, 3063-7	2.1	693
27	Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. <i>Blood</i> , 2002 , 100, 4337-43	2.1	297
26	Thalidomide: emerging role in cancer medicine. <i>Annual Review of Medicine</i> , 2002 , 53, 629-57	16.8	117
25	NF-kappa B as a therapeutic target in multiple myeloma. <i>Journal of Biological Chemistry</i> , 2002 , 277, 16639-47		723
24	Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. <i>Blood</i> , 2002 , 99, 4525-30	2.1	576
23	Cytokines modulate telomerase activity in a human multiple myeloma cell line. <i>Cancer Research</i> , 2002 , 62, 3876-82	9.6	112
22	Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. <i>Cancer Research</i> , 2002 , 62, 4996-5000	9.6	300
21	The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. <i>Cancer Research</i> , 2002 , 62, 5019-26	9.6	107
20	The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma. <i>Molecular Cancer Therapeutics</i> , 2002 , 1, 539-44	5.8	88
19	Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. <i>Molecular Cancer Therapeutics</i> , 2002 , 1, 851-60	5.8	88
18	Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. <i>Blood</i> , 2001 , 98, 210-6	2.1	773
17	Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. <i>Blood</i> , 2001 , 98, 428-35	2.1	358
16	TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. <i>Blood</i> , 2001 , 98, 795-804	2.1	335
15	The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. <i>Oncogene</i> , 2001 , 20, 4519-27	8.9	336
14	Novel therapies targeting the myeloma cell and its bone marrow microenvironment. <i>Seminars in Oncology</i> , 2001 , 28, 607-12	5.3	136
13	Hepatic veno-occlusive disease following hematopoietic stem cell transplantation. <i>Acta Haematologica</i> , 2001 , 106, 57-68	2.5	58
12	Novel therapies targeting the myeloma cell and its bone marrow microenvironment. <i>Seminars in Oncology</i> , 2001 , 28, 607-612	5.3	122

11	Double high-dose chemotherapy with stem cell rescue (HD-SCR) in patients with breast cancer - effect of sequence. <i>Cancer Chemotherapy and Pharmacology</i> , 2000 , 45, 239-46	3.4	7
10	Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. <i>Blood</i> , 2000 , 96, 2943-2950	2.1	772
9	Dose-intensive therapy for limited-stage small-cell lung cancer: long-term outcome. <i>Journal of Clinical Oncology</i> , 1999 , 17, 1175	2.1	45
8	The pathology, diagnosis, and treatment of hepatic veno-occlusive disease: current status and novel approaches. <i>British Journal of Haematology</i> , 1999 , 107, 485-93	4.4	72
7	Neutropenic enterocolitis as a complication of high dose chemotherapy with stem cell rescue in patients with solid tumors 1998 , 83, 409-414		33
6	Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders. <i>Drugs</i> , 1998 , 56, 307-35	11.6	181
5	Prevention and treatment of hepatic venocclusive disease after high-dose cytoreductive therapy. <i>Leukemia and Lymphoma</i> , 1998 , 31, 267-77	1.8	23
4	Neutropenic enterocolitis as a complication of high dose chemotherapy with stem cell rescue in patients with solid tumors 1998 , 83, 409		1
3	Treatment of relapsed/refractory myeloma 144-166		
2	Antibody-drug conjugate therapies in multiple myeloma - what's next on the horizon?. <i>Exploration of Targeted Anti-tumor Therapy</i> , 617-626	2.5	1
1	TREATMENT OF RELAPSED AND RELAPSED/REFRACTORY MULTIPLE MYELOMA 46-63		